BMPR2
Normalized values from positional scanning peptide array
TYR version of PSPA with Y as phospho-acceptor
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | S1068 | Sugiyama | POTEF A26C1B | SLSTFQQMWISKQEyDEsGPsIVHRKCL_____________ |
| O43852 | S69 | Sugiyama | CALU | HDAFLGAEEAKtFDQLtPEEsKERLGKIVSKIDGDKDGFVt |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04083 | S173 | Sugiyama | ANXA1 ANX1 LPC1 | NRVYREELKRDLAKDItsDtsGDFRNALLsLAKGDRsEDFG |
| P04406 | Y320 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE_____ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05787 | S291 | Sugiyama | KRT8 CYK8 | ANRsRAEAEsMyQIKyEELQsLAGKHGDDLRRTKTEISEMN |
| P06733 | T100 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | KKLNVtEQEKIDKLMIEMDGtENKsKFGANAILGVsLAVCK |
| P06733 | Y287 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | PsRyIsPDQLADLyKsFIKDyPVVsIEDPFDQDDWGAWQKF |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08195 | S598 | Sugiyama | SLC3A2 MDU1 | LQASDLPASASLPAKADLLLstQPGREEGsPLELERLKLEP |
| P08238 | S460 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQ |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P0CG38 | S1068 | Sugiyama | POTEI | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG39 | S1031 | Sugiyama | POTEJ | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P13674 | Y282 | Sugiyama | P4HA1 P4HA | ASDDQSDQKTTPKKKGVAVDyLPERQKyEMLCRGEGIKMTP |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15311 | S539 | Sugiyama | EZR VIL2 | TEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNENMR |
| P23396 | S35 | Sugiyama | RPS3 OK/SW-cl.26 | GIFKAELNEFLtRELAEDGysGVEVRVtPTRTEIIILATRT |
| P25205 | Y19 | Sugiyama | MCM3 | __MAGtVVLDDVELREAQRDyLDFLDDEEDQGIyQsKVREL |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P29692 | S162 | Sugiyama | EEF1D EF1D | AKKPAtPAEDDEDDDIDLFGsDNEEEDKEAAQLREERLRQY |
| P30050 | S138 | Sugiyama | RPL12 | HRSLARELsGtIKEILGtAQsVGCNVDGRHPHDIIDDINsG |
| P35613 | S279 | Sugiyama | BSG UNQ6505/PRO21383 | TDSEDKALMNGSESRFFVsssQGRSELHIENLNMEADPGQy |
| P38646 | T94 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | QAKVLENAEGARttPsVVAFtADGERLVGMPAKRQAVtNPN |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60660 | Y89 | Sugiyama | MYL6 | HFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMGAEI |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S368 | Sugiyama | ACTB | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | Y53 | Sugiyama | ACTB | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | Y55 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S368 | Sugiyama | ACTG1 ACTG | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | Y53 | Sugiyama | ACTG1 ACTG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | Y54 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | Y55 | Sugiyama | ACTC1 ACTC | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | Y55 | Sugiyama | ACTA1 ACTA | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q01105 | S166 | Sugiyama | SET | yFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQT |
| Q01105 | S168 | Sugiyama | SET | ENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQN |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q13873 | S1030 | Sugiyama | BMPR2 PPH1 | HSKSSTAVyLAEGGTATTMVsKDIGMNCL____________ |
| Q13873 | S185 | Sugiyama | BMPR2 PPH1 | IVALCFGYRMLTGDRKQGLHsMNMMEAAAsEPSLDLDNLKL |
| Q13873 | S194 | Sugiyama | BMPR2 PPH1 | MLTGDRKQGLHsMNMMEAAAsEPSLDLDNLKLLELIGRGRY |
| Q13873 | S233 | Sugiyama | BMPR2 PPH1 | RYGAVYKGSLDERPVAVKVFsFANRQNFINEKNIYRVPLME |
| Q13873 | S375 | Sugiyama | BMPR2 PPH1 | SMRLTGNRLVRPGEEDNAAIsEVGtIRYMAPEVLEGAVNLR |
| Q13873 | S513 | Sugiyama | BMPR2 PPH1 | TAQCAEERMAELMMIWERNKsVsPtVNPMsTAMQNERNLSH |
| Q13873 | S515 | Sugiyama | BMPR2 PPH1 | QCAEERMAELMMIWERNKsVsPtVNPMsTAMQNERNLSHNR |
| Q13873 | S522 | Sugiyama | BMPR2 PPH1 | AELMMIWERNKsVsPtVNPMsTAMQNERNLSHNRRVPKIGP |
| Q13873 | S680 | Sugiyama | BMPR2 PPH1 | EEDLETNKLDPKEVDKNLKEssDENLMEHsLKQFSGPDPLS |
| Q13873 | S681 | Sugiyama | BMPR2 PPH1 | EDLETNKLDPKEVDKNLKEssDENLMEHsLKQFSGPDPLSS |
| Q13873 | S689 | Sugiyama | BMPR2 PPH1 | DPKEVDKNLKEssDENLMEHsLKQFSGPDPLSSTSSSLLyP |
| Q13873 | S862 | Sugiyama | BMPR2 PPH1 | RAQEMLQNQFIGEDTRLNINssPDEHEPLLRREQQAGHDEG |
| Q13873 | T517 | Sugiyama | BMPR2 PPH1 | AEERMAELMMIWERNKsVsPtVNPMsTAMQNERNLSHNRRV |
| Q13873 | T793 | Sugiyama | BMPR2 PPH1 | FGSKHKSNLKQVETGVAKMNtINAAEPHVVtVtMNGVAGRN |
| Q13873 | T803 | Sugiyama | BMPR2 PPH1 | QVETGVAKMNtINAAEPHVVtVtMNGVAGRNHSVNsHAATt |
| Q13873 | T805 | Sugiyama | BMPR2 PPH1 | ETGVAKMNtINAAEPHVVtVtMNGVAGRNHSVNsHAATtQY |
| Q13873 | Y1018 | Sugiyama | BMPR2 PPH1 | CEVNNNGSNRAVHSKSSTAVyLAEGGTATTMVsKDIGMNCL |
| Q15181 | S127 | Sugiyama | PPA1 IOPPP PP | NDKHTGCCGDNDPIDVCEIGsKVCARGEIIGVKVLGILAMI |
| Q15293 | S80 | Sugiyama | RCN1 RCN | HEAFLGKEDsKtFDQLtPDEsKERLGKIVDRIDNDGDGFVt |
| Q15293 | Y278 | Sugiyama | RCN1 RCN | LNKDGKLDKDEIRHWILPQDyDHAQAEARHLVyESDKNKDE |
| Q562R1 | T107 | Sugiyama | ACTBL2 | WYHTFYNELRVAPDEHPILLtEAPLNPKINREKMTQIMFEA |
| Q6S8J3 | S1068 | Sugiyama | POTEE A26C1A POTE2 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q99676 | T167 | Sugiyama | ZNF184 | EGSLERQQANQQTLPKEIKVtEKTIPSWEKGPVNNEFGKSV |
| Q9BYX7 | S368 | Sugiyama | POTEKP ACTBL3 FKSG30 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q9NRX4 | T119 | Sugiyama | PHPT1 PHP14 CGI-202 HSPC141 | PAQHAISTEKIKAKyPDyEVtWANDGy______________ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 7.216450e-15 | 14.142 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.093459e-12 | 11.961 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.442724e-11 | 10.612 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 7.199796e-11 | 10.143 | 0 | 0 |
| M Phase | R-HSA-68886 | 8.050725e-10 | 9.094 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.099539e-09 | 8.292 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.543974e-08 | 7.811 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.046342e-08 | 7.094 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 8.459117e-08 | 7.073 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.233071e-07 | 6.909 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.623028e-07 | 6.790 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.291994e-07 | 6.640 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.197292e-07 | 6.658 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.478838e-07 | 6.459 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 6.467429e-07 | 6.189 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 6.586954e-07 | 6.181 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.312140e-06 | 5.882 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.497256e-06 | 5.825 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.657519e-06 | 5.781 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.946906e-06 | 5.711 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.914350e-06 | 5.535 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.349424e-06 | 5.475 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 4.516403e-06 | 5.345 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 8.843356e-06 | 5.053 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 9.242616e-06 | 5.034 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.109592e-05 | 4.955 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.299802e-05 | 4.886 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.708474e-05 | 4.767 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.743634e-05 | 4.759 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.941962e-05 | 4.712 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.110819e-05 | 4.676 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.262291e-05 | 4.645 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.726656e-05 | 4.564 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.138242e-05 | 4.503 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.288035e-05 | 4.483 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.403296e-05 | 4.468 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.382159e-05 | 4.471 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.967749e-05 | 4.401 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.963364e-05 | 4.402 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.020728e-05 | 4.396 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.946325e-05 | 4.404 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.117710e-05 | 4.385 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 5.115797e-05 | 4.291 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 5.424306e-05 | 4.266 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.289273e-05 | 4.277 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 6.437388e-05 | 4.191 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 7.014400e-05 | 4.154 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 6.949001e-05 | 4.158 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 7.316500e-05 | 4.136 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.133256e-05 | 4.147 | 0 | 0 |
| Kinesins | R-HSA-983189 | 9.307440e-05 | 4.031 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 9.774736e-05 | 4.010 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.039893e-04 | 3.983 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.043747e-04 | 3.981 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.117178e-04 | 3.952 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.270931e-04 | 3.896 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 1.502413e-04 | 3.823 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.476281e-04 | 3.831 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.502413e-04 | 3.823 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.589738e-04 | 3.799 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.770562e-04 | 3.752 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.897824e-04 | 3.722 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.043189e-04 | 3.690 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 2.160395e-04 | 3.665 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.146377e-04 | 3.668 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.242897e-04 | 3.649 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.242897e-04 | 3.649 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.414430e-04 | 3.617 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.414430e-04 | 3.617 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.633822e-04 | 3.579 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.633822e-04 | 3.579 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.766126e-04 | 3.558 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.410819e-04 | 3.467 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.412624e-04 | 3.467 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 3.633099e-04 | 3.440 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 3.903135e-04 | 3.409 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 4.137310e-04 | 3.383 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 4.591588e-04 | 3.338 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.942504e-04 | 3.306 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 5.348702e-04 | 3.272 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 5.454216e-04 | 3.263 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 5.779176e-04 | 3.238 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 5.779176e-04 | 3.238 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.309320e-04 | 3.200 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 6.473045e-04 | 3.189 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 6.494372e-04 | 3.187 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 6.536454e-04 | 3.185 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 6.571682e-04 | 3.182 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 7.199362e-04 | 3.143 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 7.446345e-04 | 3.128 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 9.306045e-04 | 3.031 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 9.306045e-04 | 3.031 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 9.493883e-04 | 3.023 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 9.934190e-04 | 3.003 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.013342e-03 | 2.994 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.023370e-03 | 2.990 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.042524e-03 | 2.982 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.085621e-03 | 2.964 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.251704e-03 | 2.902 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.251704e-03 | 2.902 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.189867e-03 | 2.925 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.189867e-03 | 2.925 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.249673e-03 | 2.903 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.267758e-03 | 2.897 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.274461e-03 | 2.895 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.388276e-03 | 2.858 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.392900e-03 | 2.856 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.392900e-03 | 2.856 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.398148e-03 | 2.854 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.502029e-03 | 2.823 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.594408e-03 | 2.797 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.674897e-03 | 2.776 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.729541e-03 | 2.762 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.741539e-03 | 2.759 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.786944e-03 | 2.748 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.872273e-03 | 2.728 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.969663e-03 | 2.706 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.978931e-03 | 2.704 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.041801e-03 | 2.690 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.042861e-03 | 2.690 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 2.205062e-03 | 2.657 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.208500e-03 | 2.656 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.213851e-03 | 2.655 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.439658e-03 | 2.613 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.447495e-03 | 2.611 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.447495e-03 | 2.611 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.465117e-03 | 2.608 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.494814e-03 | 2.603 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.547447e-03 | 2.594 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.555978e-03 | 2.592 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.581113e-03 | 2.588 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.687023e-03 | 2.571 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.925940e-03 | 2.534 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 2.751693e-03 | 2.560 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.795072e-03 | 2.554 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.864013e-03 | 2.543 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.992460e-03 | 2.524 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.037260e-03 | 2.518 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 3.039552e-03 | 2.517 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 3.266108e-03 | 2.486 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 3.369546e-03 | 2.472 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 3.308122e-03 | 2.480 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 3.308122e-03 | 2.480 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 3.296764e-03 | 2.482 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 3.305839e-03 | 2.481 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 3.305839e-03 | 2.481 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 3.595611e-03 | 2.444 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.431253e-03 | 2.465 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.771638e-03 | 2.423 | 0 | 0 |
| Depurination | R-HSA-73927 | 3.808427e-03 | 2.419 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 3.858002e-03 | 2.414 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 4.054933e-03 | 2.392 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 4.078346e-03 | 2.390 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 4.537996e-03 | 2.343 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 4.537996e-03 | 2.343 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 4.537996e-03 | 2.343 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 4.537996e-03 | 2.343 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.408530e-03 | 2.356 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.408530e-03 | 2.356 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.490785e-03 | 2.348 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.199006e-03 | 2.377 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 4.636861e-03 | 2.334 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.669388e-03 | 2.331 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 4.674123e-03 | 2.330 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 4.779530e-03 | 2.321 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 4.779530e-03 | 2.321 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.805064e-03 | 2.318 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.844427e-03 | 2.315 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 5.501182e-03 | 2.260 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 5.682804e-03 | 2.245 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 5.682804e-03 | 2.245 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 5.173418e-03 | 2.286 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 5.497559e-03 | 2.260 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 5.373849e-03 | 2.270 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.501182e-03 | 2.260 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 5.595891e-03 | 2.252 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 5.209458e-03 | 2.283 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 5.612743e-03 | 2.251 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 5.781571e-03 | 2.238 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 5.872095e-03 | 2.231 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 5.872095e-03 | 2.231 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 5.993103e-03 | 2.222 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 5.993103e-03 | 2.222 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 5.993103e-03 | 2.222 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.003934e-03 | 2.222 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 6.054459e-03 | 2.218 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 6.054459e-03 | 2.218 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.200445e-03 | 2.208 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 6.221046e-03 | 2.206 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 6.260139e-03 | 2.203 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 6.380474e-03 | 2.195 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 6.663098e-03 | 2.176 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 7.157433e-03 | 2.145 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 6.435907e-03 | 2.191 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.459747e-03 | 2.190 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 6.967947e-03 | 2.157 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.157433e-03 | 2.145 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.435907e-03 | 2.191 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 7.470587e-03 | 2.127 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 7.470587e-03 | 2.127 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.549807e-03 | 2.122 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.549807e-03 | 2.122 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.590696e-03 | 2.120 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 8.141797e-03 | 2.089 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 8.222844e-03 | 2.085 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 8.255224e-03 | 2.083 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 9.027701e-03 | 2.044 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 9.027701e-03 | 2.044 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 9.107331e-03 | 2.041 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 9.162475e-03 | 2.038 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 9.172092e-03 | 2.038 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 9.248101e-03 | 2.034 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 9.248101e-03 | 2.034 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.459629e-03 | 2.024 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 9.466234e-03 | 2.024 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.090522e-02 | 1.962 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.031349e-02 | 1.987 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.039883e-02 | 1.983 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.013860e-02 | 1.994 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.084048e-02 | 1.965 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 9.871252e-03 | 2.006 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.083748e-02 | 1.965 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.090522e-02 | 1.962 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.067743e-02 | 1.972 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.140535e-02 | 1.943 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.186669e-02 | 1.926 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.186669e-02 | 1.926 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 1.194569e-02 | 1.923 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.197974e-02 | 1.922 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.197974e-02 | 1.922 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.286956e-02 | 1.890 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.314005e-02 | 1.881 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.349803e-02 | 1.870 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.352514e-02 | 1.869 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.383158e-02 | 1.859 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 1.383158e-02 | 1.859 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.383158e-02 | 1.859 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.383158e-02 | 1.859 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.383158e-02 | 1.859 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.417263e-02 | 1.849 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.432074e-02 | 1.844 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.432074e-02 | 1.844 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.441952e-02 | 1.841 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.443632e-02 | 1.841 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.469697e-02 | 1.833 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.469697e-02 | 1.833 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.490020e-02 | 1.827 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.498766e-02 | 1.824 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.519646e-02 | 1.818 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.511956e-02 | 1.820 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.663509e-02 | 1.779 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.683912e-02 | 1.774 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.683912e-02 | 1.774 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.753393e-02 | 1.756 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.607695e-02 | 1.794 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.637692e-02 | 1.786 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.511956e-02 | 1.820 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.519646e-02 | 1.818 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.547489e-02 | 1.810 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.763578e-02 | 1.754 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.792769e-02 | 1.746 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.797630e-02 | 1.745 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.831256e-02 | 1.737 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.857071e-02 | 1.731 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.879322e-02 | 1.726 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.885962e-02 | 1.724 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.910864e-02 | 1.719 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.919927e-02 | 1.717 | 1 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.924697e-02 | 1.716 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.984971e-02 | 1.702 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.996013e-02 | 1.700 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.025382e-02 | 1.693 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.025382e-02 | 1.693 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.025382e-02 | 1.693 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.025382e-02 | 1.693 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.148612e-02 | 1.668 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 2.148612e-02 | 1.668 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.399345e-02 | 1.620 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.399345e-02 | 1.620 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.399345e-02 | 1.620 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.399345e-02 | 1.620 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.399345e-02 | 1.620 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.399345e-02 | 1.620 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.328886e-02 | 1.633 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.170253e-02 | 1.663 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.067468e-02 | 1.685 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 2.202877e-02 | 1.657 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.166750e-02 | 1.664 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.252113e-02 | 1.647 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.202763e-02 | 1.657 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.185330e-02 | 1.660 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.228105e-02 | 1.652 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.148612e-02 | 1.668 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 2.350884e-02 | 1.629 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.420808e-02 | 1.616 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.202763e-02 | 1.657 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.191249e-02 | 1.659 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.350884e-02 | 1.629 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.350736e-02 | 1.629 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.073004e-02 | 1.683 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.244894e-02 | 1.649 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.356792e-02 | 1.628 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.443295e-02 | 1.612 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.066911e-02 | 1.685 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 2.185330e-02 | 1.660 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.121987e-02 | 1.673 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.380042e-02 | 1.623 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.476023e-02 | 1.606 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 2.485193e-02 | 1.605 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.562590e-02 | 1.591 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 2.562590e-02 | 1.591 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.727250e-02 | 1.564 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 2.727250e-02 | 1.564 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.741371e-02 | 1.562 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.749008e-02 | 1.561 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.808135e-02 | 1.552 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 2.821223e-02 | 1.550 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 2.912800e-02 | 1.536 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 2.933277e-02 | 1.533 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.982335e-02 | 1.525 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.982335e-02 | 1.525 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 2.988726e-02 | 1.525 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.028914e-02 | 1.519 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.201162e-02 | 1.495 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.228941e-02 | 1.491 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 3.333295e-02 | 1.477 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.336765e-02 | 1.477 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.424770e-02 | 1.465 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.504194e-02 | 1.455 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.625189e-02 | 1.441 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 3.655953e-02 | 1.437 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.658952e-02 | 1.437 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.747151e-02 | 1.426 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.788019e-02 | 1.422 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.792737e-02 | 1.421 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.792737e-02 | 1.421 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 3.803215e-02 | 1.420 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 3.885702e-02 | 1.411 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 3.908135e-02 | 1.408 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 3.908135e-02 | 1.408 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 4.311669e-02 | 1.365 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 4.311669e-02 | 1.365 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 4.311669e-02 | 1.365 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 4.386356e-02 | 1.358 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 4.386356e-02 | 1.358 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.923404e-02 | 1.308 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 4.923404e-02 | 1.308 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.923404e-02 | 1.308 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 4.384862e-02 | 1.358 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.452113e-02 | 1.351 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.452113e-02 | 1.351 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.942131e-02 | 1.404 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.216725e-02 | 1.375 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.752068e-02 | 1.323 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 4.001917e-02 | 1.398 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 4.391074e-02 | 1.357 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.534629e-02 | 1.343 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 4.923404e-02 | 1.308 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 4.087780e-02 | 1.389 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.452113e-02 | 1.351 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.331824e-02 | 1.363 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 4.238553e-02 | 1.373 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.089432e-02 | 1.388 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.880150e-02 | 1.312 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.837336e-02 | 1.315 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.752068e-02 | 1.323 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.837336e-02 | 1.315 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 4.496579e-02 | 1.347 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 4.505174e-02 | 1.346 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.924649e-02 | 1.308 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.955530e-02 | 1.305 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.995196e-02 | 1.301 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.995196e-02 | 1.301 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.995196e-02 | 1.301 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 4.995196e-02 | 1.301 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 5.014587e-02 | 1.300 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 5.122304e-02 | 1.291 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 5.122304e-02 | 1.291 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.185376e-02 | 1.285 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 5.237111e-02 | 1.281 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 5.237111e-02 | 1.281 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.435560e-02 | 1.265 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 5.439134e-02 | 1.264 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 5.451513e-02 | 1.263 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.451513e-02 | 1.263 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 5.638724e-02 | 1.249 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 5.650348e-02 | 1.248 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 5.650348e-02 | 1.248 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 5.706673e-02 | 1.244 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 5.996966e-02 | 1.222 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.996966e-02 | 1.222 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 6.017501e-02 | 1.221 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.017501e-02 | 1.221 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 6.190918e-02 | 1.208 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 6.190918e-02 | 1.208 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.207530e-02 | 1.207 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.207530e-02 | 1.207 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.207530e-02 | 1.207 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.207530e-02 | 1.207 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 6.236410e-02 | 1.205 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 6.236410e-02 | 1.205 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 6.325065e-02 | 1.199 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 6.408166e-02 | 1.193 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 6.462189e-02 | 1.190 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 6.462189e-02 | 1.190 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 6.462189e-02 | 1.190 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 6.500367e-02 | 1.187 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.595280e-02 | 1.181 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 6.595280e-02 | 1.181 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 6.595280e-02 | 1.181 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 6.612109e-02 | 1.180 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 6.713125e-02 | 1.173 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 6.866411e-02 | 1.163 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.887137e-02 | 1.162 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 6.887137e-02 | 1.162 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 7.248610e-02 | 1.140 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 7.248610e-02 | 1.140 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 7.290837e-02 | 1.137 | 0 | 0 |
| Defective Base Excision Repair Associated with OGG1 | R-HSA-9656249 | 8.733147e-02 | 1.059 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 7.681641e-02 | 1.115 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 7.681641e-02 | 1.115 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 7.681641e-02 | 1.115 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 8.366477e-02 | 1.077 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 9.493350e-02 | 1.023 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 9.493350e-02 | 1.023 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 9.299242e-02 | 1.032 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.609694e-02 | 1.119 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 9.679625e-02 | 1.014 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 9.679625e-02 | 1.014 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.022574e-02 | 1.045 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 8.675103e-02 | 1.062 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 8.675103e-02 | 1.062 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 8.675103e-02 | 1.062 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 8.711395e-02 | 1.060 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 8.711395e-02 | 1.060 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 8.417593e-02 | 1.075 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 9.679625e-02 | 1.014 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 8.224128e-02 | 1.085 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 7.681641e-02 | 1.115 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 8.366477e-02 | 1.077 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 8.239981e-02 | 1.084 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 9.493350e-02 | 1.023 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 9.914432e-02 | 1.004 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 7.850790e-02 | 1.105 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 8.118417e-02 | 1.091 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 7.681641e-02 | 1.115 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 8.711395e-02 | 1.060 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 8.118417e-02 | 1.091 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 8.366477e-02 | 1.077 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 9.493350e-02 | 1.023 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 9.493350e-02 | 1.023 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 9.493350e-02 | 1.023 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 7.818651e-02 | 1.107 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 9.493350e-02 | 1.023 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 9.022574e-02 | 1.045 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.225020e-02 | 1.035 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 7.810842e-02 | 1.107 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 7.857978e-02 | 1.105 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 7.631123e-02 | 1.117 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 7.609694e-02 | 1.119 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.004450e-01 | 0.998 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.009365e-01 | 0.996 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.024927e-01 | 0.989 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 1.024927e-01 | 0.989 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 1.024927e-01 | 0.989 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 1.027751e-01 | 0.988 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.027751e-01 | 0.988 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.028252e-01 | 0.988 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 1.063414e-01 | 0.973 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 1.065730e-01 | 0.972 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.076383e-01 | 0.968 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.084191e-01 | 0.965 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.084191e-01 | 0.965 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.086813e-01 | 0.964 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.086813e-01 | 0.964 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.086813e-01 | 0.964 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.086813e-01 | 0.964 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.094230e-01 | 0.961 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.094783e-01 | 0.961 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.105222e-01 | 0.957 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.105222e-01 | 0.957 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.118118e-01 | 0.952 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.118118e-01 | 0.952 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.118118e-01 | 0.952 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.118118e-01 | 0.952 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.120433e-01 | 0.951 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.124163e-01 | 0.949 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.124609e-01 | 0.949 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.134387e-01 | 0.945 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.178302e-01 | 0.929 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.215565e-01 | 0.915 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 1.217126e-01 | 0.915 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.233475e-01 | 0.909 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 1.233475e-01 | 0.909 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.247734e-01 | 0.904 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.247734e-01 | 0.904 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.247734e-01 | 0.904 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.247734e-01 | 0.904 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.249086e-01 | 0.903 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.252727e-01 | 0.902 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.255585e-01 | 0.901 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.258030e-01 | 0.900 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.258426e-01 | 0.900 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.258426e-01 | 0.900 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.274477e-01 | 0.895 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.307812e-01 | 0.883 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.336194e-01 | 0.874 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.336194e-01 | 0.874 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 1.355345e-01 | 0.868 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 1.360381e-01 | 0.866 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.360381e-01 | 0.866 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.360381e-01 | 0.866 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.380176e-01 | 0.860 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.382947e-01 | 0.859 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.394978e-01 | 0.855 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.399821e-01 | 0.854 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 1.399821e-01 | 0.854 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.399821e-01 | 0.854 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 1.399821e-01 | 0.854 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 1.403084e-01 | 0.853 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.404567e-01 | 0.852 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 1.405202e-01 | 0.852 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 1.410180e-01 | 0.851 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.444849e-01 | 0.840 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.447123e-01 | 0.839 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.447123e-01 | 0.839 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.447123e-01 | 0.839 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 1.447123e-01 | 0.839 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 1.447123e-01 | 0.839 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.453553e-01 | 0.838 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.469469e-01 | 0.833 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.481501e-01 | 0.829 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.483438e-01 | 0.829 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.483438e-01 | 0.829 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.490719e-01 | 0.827 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.490719e-01 | 0.827 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.490719e-01 | 0.827 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.490719e-01 | 0.827 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.490719e-01 | 0.827 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.490719e-01 | 0.827 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.497619e-01 | 0.825 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.508462e-01 | 0.821 | 0 | 0 |
| Defective OGG1 Substrate Binding | R-HSA-9656255 | 1.508462e-01 | 0.821 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.508462e-01 | 0.821 | 0 | 0 |
| Defective OGG1 Localization | R-HSA-9657050 | 1.508462e-01 | 0.821 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.508462e-01 | 0.821 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.508462e-01 | 0.821 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.975194e-01 | 0.704 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.975194e-01 | 0.704 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.840192e-01 | 0.735 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 1.840192e-01 | 0.735 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.661601e-01 | 0.779 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.257210e-01 | 0.646 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.257210e-01 | 0.646 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.257210e-01 | 0.646 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.257210e-01 | 0.646 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.257210e-01 | 0.646 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 2.257210e-01 | 0.646 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 2.257210e-01 | 0.646 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 2.257210e-01 | 0.646 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 1.983858e-01 | 0.702 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.983858e-01 | 0.702 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.751836e-01 | 0.757 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.751836e-01 | 0.757 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.028794e-01 | 0.693 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.785498e-01 | 0.748 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.580214e-01 | 0.801 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 1.580214e-01 | 0.801 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.580214e-01 | 0.801 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.030204e-01 | 0.692 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 1.776436e-01 | 0.750 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.776436e-01 | 0.750 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.538125e-01 | 0.813 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.538125e-01 | 0.813 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.239577e-01 | 0.650 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.239577e-01 | 0.650 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.723844e-01 | 0.764 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 1.723844e-01 | 0.764 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.654971e-01 | 0.781 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 1.798491e-01 | 0.745 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 2.056326e-01 | 0.687 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.698359e-01 | 0.770 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 2.195595e-01 | 0.658 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.598064e-01 | 0.796 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.621486e-01 | 0.790 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 1.723844e-01 | 0.764 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.073759e-01 | 0.683 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.937848e-01 | 0.713 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 2.130310e-01 | 0.672 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.082855e-01 | 0.681 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 2.257210e-01 | 0.646 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.840192e-01 | 0.735 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.661601e-01 | 0.779 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.218151e-01 | 0.654 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.028794e-01 | 0.693 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.894912e-01 | 0.722 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.661601e-01 | 0.779 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.661601e-01 | 0.779 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 1.789446e-01 | 0.747 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.239577e-01 | 0.650 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.035505e-01 | 0.691 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.010921e-01 | 0.697 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.009612e-01 | 0.697 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.560464e-01 | 0.807 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 2.186428e-01 | 0.660 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.654971e-01 | 0.781 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.585351e-01 | 0.800 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.839261e-01 | 0.735 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.610895e-01 | 0.793 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.033281e-01 | 0.692 | 1 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.850038e-01 | 0.733 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.712967e-01 | 0.766 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.690572e-01 | 0.772 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.137431e-01 | 0.670 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 1.840192e-01 | 0.735 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.804330e-01 | 0.744 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.121169e-01 | 0.673 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 1.886843e-01 | 0.724 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.946465e-01 | 0.711 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 2.257210e-01 | 0.646 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 1.804330e-01 | 0.744 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.105437e-01 | 0.677 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.257210e-01 | 0.646 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.073177e-01 | 0.683 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.690572e-01 | 0.772 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.258097e-01 | 0.646 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 2.258097e-01 | 0.646 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.265061e-01 | 0.645 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.270201e-01 | 0.644 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.319134e-01 | 0.635 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 2.319134e-01 | 0.635 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.322975e-01 | 0.634 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.322975e-01 | 0.634 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.322975e-01 | 0.634 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 2.322975e-01 | 0.634 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 2.322975e-01 | 0.634 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 2.329956e-01 | 0.633 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 2.329956e-01 | 0.633 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 2.366480e-01 | 0.626 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 2.374740e-01 | 0.624 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 2.403596e-01 | 0.619 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 2.403596e-01 | 0.619 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.403596e-01 | 0.619 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.417283e-01 | 0.617 | 0 | 0 |
| Defective OGG1 Substrate Processing | R-HSA-9656256 | 2.789452e-01 | 0.554 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.789452e-01 | 0.554 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.789452e-01 | 0.554 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.789452e-01 | 0.554 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.789452e-01 | 0.554 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.789452e-01 | 0.554 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.789452e-01 | 0.554 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.789452e-01 | 0.554 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.789452e-01 | 0.554 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 2.789452e-01 | 0.554 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.789452e-01 | 0.554 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.789452e-01 | 0.554 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 2.789452e-01 | 0.554 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 2.572724e-01 | 0.590 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.572724e-01 | 0.590 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.572724e-01 | 0.590 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.572724e-01 | 0.590 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.572724e-01 | 0.590 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective TPMT causes TPMT deficiency | R-HSA-5578995 | 3.877260e-01 | 0.411 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.877260e-01 | 0.411 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.877260e-01 | 0.411 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective SLC17A5 causes Salla disease (SD) and ISSD | R-HSA-5619035 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.877260e-01 | 0.411 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 3.877260e-01 | 0.411 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.877260e-01 | 0.411 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 3.172642e-01 | 0.499 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 3.172642e-01 | 0.499 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.172642e-01 | 0.499 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 3.172642e-01 | 0.499 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 3.172642e-01 | 0.499 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.172642e-01 | 0.499 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 3.172642e-01 | 0.499 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 3.172642e-01 | 0.499 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 3.172642e-01 | 0.499 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 3.172642e-01 | 0.499 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 3.172642e-01 | 0.499 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 2.689880e-01 | 0.570 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 2.689880e-01 | 0.570 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 2.689880e-01 | 0.570 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 2.689880e-01 | 0.570 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.674767e-01 | 0.573 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.674767e-01 | 0.573 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.674767e-01 | 0.573 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.674767e-01 | 0.573 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.674767e-01 | 0.573 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.674767e-01 | 0.573 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.674767e-01 | 0.573 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.674767e-01 | 0.573 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.674767e-01 | 0.573 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.130677e-01 | 0.504 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.130677e-01 | 0.504 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 3.760637e-01 | 0.425 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.760637e-01 | 0.425 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.760637e-01 | 0.425 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.760637e-01 | 0.425 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 3.760637e-01 | 0.425 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 3.760637e-01 | 0.425 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 3.760637e-01 | 0.425 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 4.801011e-01 | 0.319 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.801011e-01 | 0.319 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 4.801011e-01 | 0.319 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 4.801011e-01 | 0.319 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 4.801011e-01 | 0.319 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 2.620313e-01 | 0.582 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.620313e-01 | 0.582 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.620313e-01 | 0.582 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.035166e-01 | 0.518 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.551684e-01 | 0.593 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.551684e-01 | 0.593 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 3.572979e-01 | 0.447 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.572979e-01 | 0.447 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.929770e-01 | 0.533 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.824995e-01 | 0.549 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 3.400328e-01 | 0.468 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 4.326656e-01 | 0.364 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 4.326656e-01 | 0.364 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 4.326656e-01 | 0.364 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 4.326656e-01 | 0.364 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 4.326656e-01 | 0.364 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 3.244987e-01 | 0.489 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 3.244987e-01 | 0.489 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.627619e-01 | 0.580 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.011123e-01 | 0.397 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.011123e-01 | 0.397 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.011123e-01 | 0.397 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.011123e-01 | 0.397 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.011123e-01 | 0.397 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.449089e-01 | 0.611 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 3.766699e-01 | 0.424 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 3.766699e-01 | 0.424 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.766699e-01 | 0.424 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 3.563541e-01 | 0.448 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.387940e-01 | 0.470 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.232373e-01 | 0.490 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.232373e-01 | 0.490 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.737715e-01 | 0.563 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.052130e-01 | 0.515 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.674116e-01 | 0.435 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.674116e-01 | 0.435 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 3.674116e-01 | 0.435 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 3.674116e-01 | 0.435 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.883139e-01 | 0.411 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.883139e-01 | 0.411 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.131067e-01 | 0.384 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 4.131067e-01 | 0.384 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.324198e-01 | 0.478 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 4.201649e-01 | 0.377 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 4.490587e-01 | 0.348 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.247721e-01 | 0.372 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 4.247721e-01 | 0.372 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 4.856959e-01 | 0.314 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.856959e-01 | 0.314 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 4.856959e-01 | 0.314 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.856959e-01 | 0.314 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.856959e-01 | 0.314 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 3.901064e-01 | 0.409 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 4.517123e-01 | 0.345 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 4.517123e-01 | 0.345 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.030188e-01 | 0.519 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 3.763467e-01 | 0.424 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.241670e-01 | 0.489 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.532167e-01 | 0.344 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 4.532167e-01 | 0.344 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 4.842794e-01 | 0.315 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 4.842794e-01 | 0.315 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.417663e-01 | 0.466 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 4.827813e-01 | 0.316 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 4.827813e-01 | 0.316 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.813241e-01 | 0.318 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.654362e-01 | 0.332 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.654362e-01 | 0.332 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 3.640557e-01 | 0.439 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.030188e-01 | 0.519 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.842635e-01 | 0.546 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.091281e-01 | 0.388 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.449089e-01 | 0.611 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 3.572979e-01 | 0.447 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.980009e-01 | 0.400 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.572053e-01 | 0.447 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.544516e-01 | 0.343 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.222687e-01 | 0.374 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 3.998406e-01 | 0.398 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 3.423685e-01 | 0.466 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.011123e-01 | 0.397 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 3.397388e-01 | 0.469 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.222851e-01 | 0.374 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 2.674767e-01 | 0.573 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 2.918536e-01 | 0.535 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.449089e-01 | 0.611 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.929770e-01 | 0.533 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.440389e-01 | 0.353 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 4.201649e-01 | 0.377 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 4.532167e-01 | 0.344 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 3.329057e-01 | 0.478 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.572979e-01 | 0.447 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.011123e-01 | 0.397 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.547579e-01 | 0.342 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.220928e-01 | 0.375 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.572053e-01 | 0.447 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.863680e-01 | 0.543 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 4.813241e-01 | 0.318 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.220928e-01 | 0.375 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.638123e-01 | 0.334 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 3.572979e-01 | 0.447 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.857500e-01 | 0.544 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.131067e-01 | 0.384 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 4.842794e-01 | 0.315 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 4.364482e-01 | 0.360 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.638123e-01 | 0.334 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.104331e-01 | 0.508 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.078007e-01 | 0.512 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.540798e-01 | 0.595 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.202376e-01 | 0.377 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.763467e-01 | 0.424 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.139467e-01 | 0.503 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.572724e-01 | 0.590 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.572724e-01 | 0.590 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 2.627619e-01 | 0.580 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.857500e-01 | 0.544 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 4.440389e-01 | 0.353 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.260933e-01 | 0.487 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.501779e-01 | 0.602 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.017155e-01 | 0.396 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.857500e-01 | 0.544 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 3.815133e-01 | 0.418 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 3.104331e-01 | 0.508 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 3.932337e-01 | 0.405 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 4.540756e-01 | 0.343 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 2.964404e-01 | 0.528 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.961224e-01 | 0.402 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.856959e-01 | 0.314 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 3.815133e-01 | 0.418 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 2.846766e-01 | 0.546 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.330822e-01 | 0.477 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 4.538611e-01 | 0.343 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 2.431565e-01 | 0.614 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.330822e-01 | 0.477 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.330822e-01 | 0.477 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 4.773525e-01 | 0.321 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.991377e-01 | 0.524 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.361560e-01 | 0.360 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 3.877260e-01 | 0.411 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 3.172642e-01 | 0.499 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 3.130677e-01 | 0.504 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 3.572979e-01 | 0.447 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 3.400328e-01 | 0.468 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 4.440389e-01 | 0.353 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 3.754296e-01 | 0.425 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 4.490587e-01 | 0.348 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.799721e-01 | 0.319 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.540798e-01 | 0.595 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.431565e-01 | 0.614 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 3.244987e-01 | 0.489 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.607791e-01 | 0.443 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 3.130677e-01 | 0.504 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.513400e-01 | 0.345 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 3.365218e-01 | 0.473 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.307106e-01 | 0.481 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 3.035166e-01 | 0.518 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.723977e-01 | 0.565 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.766699e-01 | 0.424 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 4.319718e-01 | 0.365 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 4.014084e-01 | 0.396 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.247721e-01 | 0.372 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 4.326656e-01 | 0.364 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.686088e-01 | 0.433 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.059002e-01 | 0.392 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.430517e-01 | 0.354 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 4.689849e-01 | 0.329 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 3.883139e-01 | 0.411 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 4.842794e-01 | 0.315 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.059002e-01 | 0.392 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.963176e-01 | 0.528 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 4.332452e-01 | 0.363 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.645529e-01 | 0.577 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 3.766699e-01 | 0.424 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 4.540756e-01 | 0.343 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 2.802643e-01 | 0.552 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 4.607582e-01 | 0.337 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.789452e-01 | 0.554 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 2.789452e-01 | 0.554 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.572724e-01 | 0.590 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.877260e-01 | 0.411 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.877260e-01 | 0.411 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 3.172642e-01 | 0.499 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 2.689880e-01 | 0.570 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 3.760637e-01 | 0.425 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 3.760637e-01 | 0.425 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 4.801011e-01 | 0.319 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 4.801011e-01 | 0.319 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 4.801011e-01 | 0.319 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.011123e-01 | 0.397 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 2.451227e-01 | 0.611 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 3.674116e-01 | 0.435 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.440389e-01 | 0.353 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.572053e-01 | 0.447 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 4.856959e-01 | 0.314 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.856959e-01 | 0.314 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 4.517123e-01 | 0.345 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.943890e-01 | 0.404 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.718099e-01 | 0.326 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 3.572979e-01 | 0.447 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.540798e-01 | 0.595 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 4.201649e-01 | 0.377 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.883139e-01 | 0.411 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.740466e-01 | 0.562 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 2.612064e-01 | 0.583 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.011123e-01 | 0.397 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 4.059002e-01 | 0.392 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.793379e-01 | 0.421 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.793379e-01 | 0.421 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.011123e-01 | 0.397 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.532167e-01 | 0.344 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.635067e-01 | 0.439 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 3.130677e-01 | 0.504 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.760637e-01 | 0.425 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 4.827813e-01 | 0.316 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 4.532167e-01 | 0.344 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.856959e-01 | 0.314 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 2.551684e-01 | 0.593 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.173764e-01 | 0.498 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.877260e-01 | 0.411 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.035166e-01 | 0.518 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 4.131067e-01 | 0.384 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 4.440389e-01 | 0.353 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 4.540756e-01 | 0.343 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 3.943890e-01 | 0.404 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 2.674767e-01 | 0.573 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.130677e-01 | 0.504 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 3.101141e-01 | 0.508 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.478123e-01 | 0.606 | 0 | 0 |
| Diseases of Base Excision Repair | R-HSA-9605308 | 3.760637e-01 | 0.425 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.635067e-01 | 0.439 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.620313e-01 | 0.582 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.801011e-01 | 0.319 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 4.326656e-01 | 0.364 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 4.863949e-01 | 0.313 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 4.863949e-01 | 0.313 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 4.863949e-01 | 0.313 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 4.863949e-01 | 0.313 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 4.863949e-01 | 0.313 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 4.863949e-01 | 0.313 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 4.863949e-01 | 0.313 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 4.863949e-01 | 0.313 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.952050e-01 | 0.305 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 4.960189e-01 | 0.305 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.960189e-01 | 0.305 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 5.005443e-01 | 0.301 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 5.005443e-01 | 0.301 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 5.005443e-01 | 0.301 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.012047e-01 | 0.300 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 5.024153e-01 | 0.299 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 5.054456e-01 | 0.296 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.089743e-01 | 0.293 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 5.089743e-01 | 0.293 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 5.107857e-01 | 0.292 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 5.132172e-01 | 0.290 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 5.132172e-01 | 0.290 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.132172e-01 | 0.290 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 5.134667e-01 | 0.289 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 5.149327e-01 | 0.288 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.170969e-01 | 0.286 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.181864e-01 | 0.286 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 5.183536e-01 | 0.285 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.183536e-01 | 0.285 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.185598e-01 | 0.285 | 0 | 0 |
| PKA activation | R-HSA-163615 | 5.185598e-01 | 0.285 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 5.185598e-01 | 0.285 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 5.185598e-01 | 0.285 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.254572e-01 | 0.279 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.254572e-01 | 0.279 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 5.257845e-01 | 0.279 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.257845e-01 | 0.279 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.257845e-01 | 0.279 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 5.257845e-01 | 0.279 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 5.257845e-01 | 0.279 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.304511e-01 | 0.275 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.349857e-01 | 0.272 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.349868e-01 | 0.272 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 5.368303e-01 | 0.270 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 5.368303e-01 | 0.270 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 5.368303e-01 | 0.270 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 5.368303e-01 | 0.270 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 5.368303e-01 | 0.270 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 5.368303e-01 | 0.270 | 0 | 0 |
| RSK activation | R-HSA-444257 | 5.368303e-01 | 0.270 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 5.368303e-01 | 0.270 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 5.368303e-01 | 0.270 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 5.368303e-01 | 0.270 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 5.368303e-01 | 0.270 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.456628e-01 | 0.263 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.471218e-01 | 0.262 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 5.489259e-01 | 0.260 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 5.489259e-01 | 0.260 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 5.489259e-01 | 0.260 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 5.489259e-01 | 0.260 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.503051e-01 | 0.259 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 5.517273e-01 | 0.258 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 5.517273e-01 | 0.258 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 5.517273e-01 | 0.258 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 5.517273e-01 | 0.258 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.521005e-01 | 0.258 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 5.544423e-01 | 0.256 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 5.556899e-01 | 0.255 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.585438e-01 | 0.253 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.585438e-01 | 0.253 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 5.585438e-01 | 0.253 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 5.585438e-01 | 0.253 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 5.585438e-01 | 0.253 | 0 | 0 |
| 3-Methylcrotonyl-CoA carboxylase deficiency | R-HSA-9909438 | 5.585438e-01 | 0.253 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.585438e-01 | 0.253 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 5.585438e-01 | 0.253 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 5.585438e-01 | 0.253 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 5.585438e-01 | 0.253 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 5.585438e-01 | 0.253 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.585438e-01 | 0.253 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 5.585438e-01 | 0.253 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.624745e-01 | 0.250 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 5.624888e-01 | 0.250 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.640801e-01 | 0.249 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.640801e-01 | 0.249 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 5.650485e-01 | 0.248 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 5.715051e-01 | 0.243 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.721310e-01 | 0.243 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 5.828997e-01 | 0.234 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 5.836436e-01 | 0.234 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 5.837427e-01 | 0.234 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 5.837427e-01 | 0.234 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 5.837427e-01 | 0.234 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 5.837427e-01 | 0.234 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 5.837427e-01 | 0.234 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 5.837427e-01 | 0.234 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 5.837427e-01 | 0.234 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 5.837427e-01 | 0.234 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.837427e-01 | 0.234 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 5.837427e-01 | 0.234 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 5.837427e-01 | 0.234 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 5.837427e-01 | 0.234 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 5.837427e-01 | 0.234 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 5.837427e-01 | 0.234 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 5.876688e-01 | 0.231 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 5.935597e-01 | 0.227 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 5.990388e-01 | 0.223 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 5.990388e-01 | 0.223 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 5.990388e-01 | 0.223 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 5.994874e-01 | 0.222 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.004239e-01 | 0.222 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.004239e-01 | 0.222 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.004239e-01 | 0.222 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 6.004239e-01 | 0.222 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 6.004239e-01 | 0.222 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.004239e-01 | 0.222 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 6.004239e-01 | 0.222 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 6.004239e-01 | 0.222 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.004239e-01 | 0.222 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 6.050841e-01 | 0.218 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 6.050860e-01 | 0.218 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 6.064815e-01 | 0.217 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 6.130608e-01 | 0.212 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 6.130608e-01 | 0.212 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.134043e-01 | 0.212 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.142023e-01 | 0.212 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 6.142023e-01 | 0.212 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 6.142023e-01 | 0.212 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 6.142023e-01 | 0.212 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 6.150427e-01 | 0.211 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 6.150427e-01 | 0.211 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.154259e-01 | 0.211 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.218330e-01 | 0.206 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.250687e-01 | 0.204 | 0 | 0 |
| Alternative complement activation | R-HSA-173736 | 6.251548e-01 | 0.204 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 6.251548e-01 | 0.204 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 6.251548e-01 | 0.204 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 6.251548e-01 | 0.204 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 6.251548e-01 | 0.204 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 6.251548e-01 | 0.204 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 6.251548e-01 | 0.204 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 6.251548e-01 | 0.204 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 6.251548e-01 | 0.204 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 6.251548e-01 | 0.204 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 6.251548e-01 | 0.204 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 6.251548e-01 | 0.204 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 6.251548e-01 | 0.204 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 6.251548e-01 | 0.204 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 6.264406e-01 | 0.203 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 6.270468e-01 | 0.203 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 6.270468e-01 | 0.203 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 6.270468e-01 | 0.203 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 6.270468e-01 | 0.203 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 6.270468e-01 | 0.203 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 6.270468e-01 | 0.203 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 6.270468e-01 | 0.203 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 6.295907e-01 | 0.201 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 6.347137e-01 | 0.197 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 6.347137e-01 | 0.197 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 6.347137e-01 | 0.197 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.347137e-01 | 0.197 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 6.347137e-01 | 0.197 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.347137e-01 | 0.197 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.347137e-01 | 0.197 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 6.359135e-01 | 0.197 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 6.368716e-01 | 0.196 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 6.370801e-01 | 0.196 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 6.433262e-01 | 0.192 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.433262e-01 | 0.192 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 6.433262e-01 | 0.192 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 6.469806e-01 | 0.189 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.469806e-01 | 0.189 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.481406e-01 | 0.188 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 6.519053e-01 | 0.186 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.522091e-01 | 0.186 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 6.572889e-01 | 0.182 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.601918e-01 | 0.180 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 6.601918e-01 | 0.180 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 6.601918e-01 | 0.180 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.601918e-01 | 0.180 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.601918e-01 | 0.180 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.653297e-01 | 0.177 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.666384e-01 | 0.176 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 6.667636e-01 | 0.176 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 6.667636e-01 | 0.176 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 6.667636e-01 | 0.176 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 6.667636e-01 | 0.176 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 6.667636e-01 | 0.176 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 6.667636e-01 | 0.176 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 6.668951e-01 | 0.176 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.668951e-01 | 0.176 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 6.668951e-01 | 0.176 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 6.709637e-01 | 0.173 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 6.709637e-01 | 0.173 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 6.709637e-01 | 0.173 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 6.709637e-01 | 0.173 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 6.727043e-01 | 0.172 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 6.727043e-01 | 0.172 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 6.727043e-01 | 0.172 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 6.727043e-01 | 0.172 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 6.727043e-01 | 0.172 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 6.764100e-01 | 0.170 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 6.764100e-01 | 0.170 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 6.764100e-01 | 0.170 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 6.764100e-01 | 0.170 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 6.794006e-01 | 0.168 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 6.817182e-01 | 0.166 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 6.817182e-01 | 0.166 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.817182e-01 | 0.166 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.817182e-01 | 0.166 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 6.817182e-01 | 0.166 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 6.817182e-01 | 0.166 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 6.817182e-01 | 0.166 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 6.817182e-01 | 0.166 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 6.817182e-01 | 0.166 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 6.817182e-01 | 0.166 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 6.817182e-01 | 0.166 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.817182e-01 | 0.166 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 6.817182e-01 | 0.166 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 6.817182e-01 | 0.166 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 6.817182e-01 | 0.166 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 6.817182e-01 | 0.166 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 6.817182e-01 | 0.166 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.829119e-01 | 0.166 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 6.846707e-01 | 0.165 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.884608e-01 | 0.162 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 6.898163e-01 | 0.161 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.933662e-01 | 0.159 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.934168e-01 | 0.159 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 6.938909e-01 | 0.159 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.952563e-01 | 0.158 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.969538e-01 | 0.157 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 6.970867e-01 | 0.157 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.970867e-01 | 0.157 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 6.970867e-01 | 0.157 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.997373e-01 | 0.155 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 6.997373e-01 | 0.155 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.027633e-01 | 0.153 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.029895e-01 | 0.153 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 7.029895e-01 | 0.153 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 7.029895e-01 | 0.153 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.029895e-01 | 0.153 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 7.029895e-01 | 0.153 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.029895e-01 | 0.153 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.035677e-01 | 0.153 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 7.035677e-01 | 0.153 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.035677e-01 | 0.153 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 7.061232e-01 | 0.151 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 7.070685e-01 | 0.151 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 7.223547e-01 | 0.141 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.229686e-01 | 0.141 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 7.237942e-01 | 0.140 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 7.249081e-01 | 0.140 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 7.249081e-01 | 0.140 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.249081e-01 | 0.140 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 7.249081e-01 | 0.140 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 7.249081e-01 | 0.140 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 7.297490e-01 | 0.137 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 7.297490e-01 | 0.137 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 7.297490e-01 | 0.137 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 7.297490e-01 | 0.137 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 7.297490e-01 | 0.137 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 7.297490e-01 | 0.137 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 7.297490e-01 | 0.137 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 7.297490e-01 | 0.137 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 7.297490e-01 | 0.137 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 7.297490e-01 | 0.137 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 7.297490e-01 | 0.137 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 7.297490e-01 | 0.137 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 7.297490e-01 | 0.137 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 7.297490e-01 | 0.137 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 7.297490e-01 | 0.137 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 7.297490e-01 | 0.137 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 7.297490e-01 | 0.137 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 7.300963e-01 | 0.137 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 7.319451e-01 | 0.136 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.332462e-01 | 0.135 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 7.358736e-01 | 0.133 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 7.358736e-01 | 0.133 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 7.358736e-01 | 0.133 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 7.358736e-01 | 0.133 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 7.358736e-01 | 0.133 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 7.358736e-01 | 0.133 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 7.358736e-01 | 0.133 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 7.377609e-01 | 0.132 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 7.447723e-01 | 0.128 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.447723e-01 | 0.128 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.447723e-01 | 0.128 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.447723e-01 | 0.128 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.447723e-01 | 0.128 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 7.457602e-01 | 0.127 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 7.457602e-01 | 0.127 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 7.495267e-01 | 0.125 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 7.498759e-01 | 0.125 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.508023e-01 | 0.124 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 7.508023e-01 | 0.124 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 7.508023e-01 | 0.124 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.508023e-01 | 0.124 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.508023e-01 | 0.124 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 7.508023e-01 | 0.124 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.558171e-01 | 0.122 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 7.558374e-01 | 0.122 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 7.612935e-01 | 0.118 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 7.615312e-01 | 0.118 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.615312e-01 | 0.118 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.625712e-01 | 0.118 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 7.645630e-01 | 0.117 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 7.645630e-01 | 0.117 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 7.655994e-01 | 0.116 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 7.655994e-01 | 0.116 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 7.693669e-01 | 0.114 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 7.705340e-01 | 0.113 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 7.705340e-01 | 0.113 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 7.705340e-01 | 0.113 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 7.705340e-01 | 0.113 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.705340e-01 | 0.113 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 7.705340e-01 | 0.113 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 7.705340e-01 | 0.113 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 7.705340e-01 | 0.113 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 7.705340e-01 | 0.113 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 7.705340e-01 | 0.113 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.705340e-01 | 0.113 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 7.705340e-01 | 0.113 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 7.705340e-01 | 0.113 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 7.705340e-01 | 0.113 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 7.705340e-01 | 0.113 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 7.705340e-01 | 0.113 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 7.705340e-01 | 0.113 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 7.705340e-01 | 0.113 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 7.705340e-01 | 0.113 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 7.747013e-01 | 0.111 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 7.747013e-01 | 0.111 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 7.747013e-01 | 0.111 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.767497e-01 | 0.110 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.779499e-01 | 0.109 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 7.789490e-01 | 0.108 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 7.804715e-01 | 0.108 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 7.811581e-01 | 0.107 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 7.860332e-01 | 0.105 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 7.865056e-01 | 0.104 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 7.865056e-01 | 0.104 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 7.923710e-01 | 0.101 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 7.923710e-01 | 0.101 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 7.923710e-01 | 0.101 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 7.923710e-01 | 0.101 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 7.923710e-01 | 0.101 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 7.923710e-01 | 0.101 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 7.923710e-01 | 0.101 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 7.923710e-01 | 0.101 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 7.923710e-01 | 0.101 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 7.925661e-01 | 0.101 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 7.925661e-01 | 0.101 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.930522e-01 | 0.101 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 7.935396e-01 | 0.100 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.946521e-01 | 0.100 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.966850e-01 | 0.099 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 7.966850e-01 | 0.099 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.966850e-01 | 0.099 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 7.982875e-01 | 0.098 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 8.051659e-01 | 0.094 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 8.051659e-01 | 0.094 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 8.051659e-01 | 0.094 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 8.051659e-01 | 0.094 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 8.051659e-01 | 0.094 | 0 | 0 |
| Biosynthesis of maresin conjugates in tissue regeneration (MCTR) | R-HSA-9026762 | 8.051659e-01 | 0.094 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 8.051659e-01 | 0.094 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.052330e-01 | 0.094 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 8.052330e-01 | 0.094 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.052330e-01 | 0.094 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.075848e-01 | 0.093 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.164030e-01 | 0.088 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.164030e-01 | 0.088 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 8.164030e-01 | 0.088 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.164030e-01 | 0.088 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.164030e-01 | 0.088 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.168445e-01 | 0.088 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 8.168445e-01 | 0.088 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 8.168445e-01 | 0.088 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 8.179492e-01 | 0.087 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 8.179492e-01 | 0.087 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 8.181859e-01 | 0.087 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 8.213191e-01 | 0.085 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.213191e-01 | 0.085 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.213191e-01 | 0.085 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 8.237462e-01 | 0.084 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.249565e-01 | 0.084 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 8.293067e-01 | 0.081 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 8.298973e-01 | 0.081 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 8.301049e-01 | 0.081 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 8.307469e-01 | 0.081 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 8.330072e-01 | 0.079 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 8.345727e-01 | 0.079 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 8.345727e-01 | 0.079 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 8.345727e-01 | 0.079 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 8.345727e-01 | 0.079 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 8.345727e-01 | 0.079 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 8.345727e-01 | 0.079 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 8.345727e-01 | 0.079 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 8.345727e-01 | 0.079 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 8.345727e-01 | 0.079 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 8.345727e-01 | 0.079 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 8.345727e-01 | 0.079 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 8.345727e-01 | 0.079 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 8.352784e-01 | 0.078 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 8.352784e-01 | 0.078 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.352784e-01 | 0.078 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.379124e-01 | 0.077 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.379124e-01 | 0.077 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 8.379124e-01 | 0.077 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.379124e-01 | 0.077 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.379124e-01 | 0.077 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 8.379124e-01 | 0.077 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.389002e-01 | 0.076 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 8.393395e-01 | 0.076 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 8.408342e-01 | 0.075 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 8.443847e-01 | 0.073 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.494854e-01 | 0.071 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.534959e-01 | 0.069 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.534959e-01 | 0.069 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.544302e-01 | 0.068 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 8.571131e-01 | 0.067 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 8.571131e-01 | 0.067 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.571131e-01 | 0.067 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 8.571131e-01 | 0.067 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 8.571131e-01 | 0.067 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 8.571131e-01 | 0.067 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 8.571131e-01 | 0.067 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.581983e-01 | 0.066 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 8.595425e-01 | 0.066 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 8.595425e-01 | 0.066 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 8.595425e-01 | 0.066 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 8.595425e-01 | 0.066 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 8.595425e-01 | 0.066 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 8.601208e-01 | 0.065 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 8.620711e-01 | 0.064 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.628961e-01 | 0.064 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.628961e-01 | 0.064 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 8.628961e-01 | 0.064 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 8.628961e-01 | 0.064 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.648464e-01 | 0.063 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.671491e-01 | 0.062 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.673830e-01 | 0.062 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 8.693500e-01 | 0.061 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.701715e-01 | 0.060 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 8.732803e-01 | 0.059 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 8.739794e-01 | 0.058 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 8.740628e-01 | 0.058 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 8.742119e-01 | 0.058 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.742119e-01 | 0.058 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 8.742119e-01 | 0.058 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 8.742119e-01 | 0.058 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 8.742119e-01 | 0.058 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 8.746487e-01 | 0.058 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 8.784650e-01 | 0.056 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.796937e-01 | 0.056 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.807445e-01 | 0.055 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 8.807445e-01 | 0.055 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 8.807445e-01 | 0.055 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 8.807445e-01 | 0.055 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.807445e-01 | 0.055 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 8.807445e-01 | 0.055 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.812139e-01 | 0.055 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 8.812636e-01 | 0.055 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 8.812636e-01 | 0.055 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.812636e-01 | 0.055 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 8.838593e-01 | 0.054 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.882012e-01 | 0.051 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.883392e-01 | 0.051 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 8.883392e-01 | 0.051 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 8.890163e-01 | 0.051 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 8.894057e-01 | 0.051 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 8.894057e-01 | 0.051 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 8.894057e-01 | 0.051 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 8.894057e-01 | 0.051 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 8.894057e-01 | 0.051 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 8.894057e-01 | 0.051 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 8.894057e-01 | 0.051 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 8.911963e-01 | 0.050 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 8.911963e-01 | 0.050 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.911963e-01 | 0.050 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 8.917118e-01 | 0.050 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 8.938347e-01 | 0.049 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.938347e-01 | 0.049 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.938347e-01 | 0.049 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.938347e-01 | 0.049 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 8.938347e-01 | 0.049 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.970032e-01 | 0.047 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.987471e-01 | 0.046 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.987471e-01 | 0.046 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.987471e-01 | 0.046 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 8.987471e-01 | 0.046 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 8.987471e-01 | 0.046 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.987471e-01 | 0.046 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.987471e-01 | 0.046 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.987471e-01 | 0.046 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.987471e-01 | 0.046 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 8.987471e-01 | 0.046 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 8.987471e-01 | 0.046 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 9.014649e-01 | 0.045 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.028799e-01 | 0.044 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 9.028799e-01 | 0.044 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.028799e-01 | 0.044 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.028799e-01 | 0.044 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 9.028799e-01 | 0.044 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.028799e-01 | 0.044 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.028799e-01 | 0.044 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.028799e-01 | 0.044 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.051968e-01 | 0.043 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 9.051968e-01 | 0.043 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.103237e-01 | 0.041 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 9.110687e-01 | 0.040 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.113394e-01 | 0.040 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 9.140330e-01 | 0.039 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 9.140330e-01 | 0.039 | 0 | 0 |
| Scavenging by Class H Receptors | R-HSA-3000497 | 9.140330e-01 | 0.039 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 9.140330e-01 | 0.039 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 9.140330e-01 | 0.039 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 9.140330e-01 | 0.039 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 9.140330e-01 | 0.039 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 9.140330e-01 | 0.039 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 9.140330e-01 | 0.039 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.148074e-01 | 0.039 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.148074e-01 | 0.039 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.148074e-01 | 0.039 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 9.148074e-01 | 0.039 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 9.148074e-01 | 0.039 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.154465e-01 | 0.038 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.192511e-01 | 0.037 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.199568e-01 | 0.036 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.199568e-01 | 0.036 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.229305e-01 | 0.035 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.241648e-01 | 0.034 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.242725e-01 | 0.034 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 9.246762e-01 | 0.034 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 9.246762e-01 | 0.034 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.253480e-01 | 0.034 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.253480e-01 | 0.034 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 9.253480e-01 | 0.034 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.253480e-01 | 0.034 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.257728e-01 | 0.033 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.257728e-01 | 0.033 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.260686e-01 | 0.033 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 9.270119e-01 | 0.033 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 9.270119e-01 | 0.033 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 9.270119e-01 | 0.033 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.270119e-01 | 0.033 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 9.270119e-01 | 0.033 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 9.270119e-01 | 0.033 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 9.270119e-01 | 0.033 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.321088e-01 | 0.031 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.322891e-01 | 0.030 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 9.322891e-01 | 0.030 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.326705e-01 | 0.030 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.326705e-01 | 0.030 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.346485e-01 | 0.029 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.346485e-01 | 0.029 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.351546e-01 | 0.029 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.351741e-01 | 0.029 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.353468e-01 | 0.029 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.353468e-01 | 0.029 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.353468e-01 | 0.029 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 9.380320e-01 | 0.028 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 9.380320e-01 | 0.028 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 9.380320e-01 | 0.028 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.380320e-01 | 0.028 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.380320e-01 | 0.028 | 0 | 0 |
| Interconversion of polyamines | R-HSA-351200 | 9.380320e-01 | 0.028 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 9.380320e-01 | 0.028 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 9.380320e-01 | 0.028 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 9.380320e-01 | 0.028 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 9.380320e-01 | 0.028 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.382938e-01 | 0.028 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.390756e-01 | 0.027 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.393059e-01 | 0.027 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 9.393059e-01 | 0.027 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 9.404203e-01 | 0.027 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.404203e-01 | 0.027 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.419315e-01 | 0.026 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.419315e-01 | 0.026 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.422596e-01 | 0.026 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.428430e-01 | 0.026 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.428430e-01 | 0.026 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.428430e-01 | 0.026 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.428430e-01 | 0.026 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.428430e-01 | 0.026 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 9.440234e-01 | 0.025 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 9.440234e-01 | 0.025 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.450900e-01 | 0.025 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 9.455570e-01 | 0.024 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.470940e-01 | 0.024 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.470940e-01 | 0.024 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.472728e-01 | 0.024 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 9.473887e-01 | 0.023 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 9.473887e-01 | 0.023 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 9.473887e-01 | 0.023 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 9.473887e-01 | 0.023 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 9.473887e-01 | 0.023 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.473887e-01 | 0.023 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 9.473887e-01 | 0.023 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 9.473887e-01 | 0.023 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 9.473887e-01 | 0.023 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 9.473887e-01 | 0.023 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.473887e-01 | 0.023 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 9.473887e-01 | 0.023 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 9.477415e-01 | 0.023 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.478813e-01 | 0.023 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 9.478986e-01 | 0.023 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.478986e-01 | 0.023 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.478986e-01 | 0.023 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 9.488981e-01 | 0.023 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.488981e-01 | 0.023 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 9.493340e-01 | 0.023 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.500535e-01 | 0.022 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.500535e-01 | 0.022 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.500535e-01 | 0.022 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.503710e-01 | 0.022 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.528886e-01 | 0.021 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 9.528886e-01 | 0.021 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.530662e-01 | 0.021 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.553331e-01 | 0.020 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 9.553331e-01 | 0.020 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 9.553331e-01 | 0.020 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.553331e-01 | 0.020 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 9.553331e-01 | 0.020 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 9.553331e-01 | 0.020 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 9.553331e-01 | 0.020 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 9.553331e-01 | 0.020 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.563902e-01 | 0.019 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.563902e-01 | 0.019 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.581783e-01 | 0.019 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 9.594916e-01 | 0.018 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.605774e-01 | 0.017 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.615134e-01 | 0.017 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.619525e-01 | 0.017 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.619525e-01 | 0.017 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.619525e-01 | 0.017 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.619525e-01 | 0.017 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.619525e-01 | 0.017 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.619525e-01 | 0.017 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.620783e-01 | 0.017 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.620783e-01 | 0.017 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 9.620783e-01 | 0.017 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.620783e-01 | 0.017 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 9.620783e-01 | 0.017 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 9.620783e-01 | 0.017 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.625827e-01 | 0.017 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.631669e-01 | 0.016 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.631669e-01 | 0.016 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.631669e-01 | 0.016 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.631669e-01 | 0.016 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.631669e-01 | 0.016 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.635596e-01 | 0.016 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.665531e-01 | 0.015 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.668298e-01 | 0.015 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.674131e-01 | 0.014 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.674131e-01 | 0.014 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 9.678052e-01 | 0.014 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.678052e-01 | 0.014 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.678052e-01 | 0.014 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 9.678052e-01 | 0.014 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.678052e-01 | 0.014 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.678052e-01 | 0.014 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.678052e-01 | 0.014 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.678052e-01 | 0.014 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 9.678052e-01 | 0.014 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.678052e-01 | 0.014 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.697279e-01 | 0.013 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.701954e-01 | 0.013 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.711021e-01 | 0.013 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.711021e-01 | 0.013 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.711021e-01 | 0.013 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.711939e-01 | 0.013 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 9.726675e-01 | 0.012 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.726675e-01 | 0.012 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.726675e-01 | 0.012 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.726675e-01 | 0.012 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.745564e-01 | 0.011 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.745564e-01 | 0.011 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.745564e-01 | 0.011 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 9.748408e-01 | 0.011 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 9.748408e-01 | 0.011 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.748408e-01 | 0.011 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.761497e-01 | 0.010 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.762311e-01 | 0.010 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.762311e-01 | 0.010 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.762311e-01 | 0.010 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 9.767957e-01 | 0.010 | 0 | 0 |
| Biosynthesis of DHA-derived sulfido conjugates | R-HSA-9026395 | 9.767957e-01 | 0.010 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.767957e-01 | 0.010 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.769167e-01 | 0.010 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.773146e-01 | 0.010 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.775437e-01 | 0.010 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.781097e-01 | 0.010 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.781097e-01 | 0.010 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.783482e-01 | 0.010 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.790387e-01 | 0.009 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.801951e-01 | 0.009 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.801951e-01 | 0.009 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.803006e-01 | 0.009 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.803006e-01 | 0.009 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 9.803006e-01 | 0.009 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.803006e-01 | 0.009 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.809653e-01 | 0.008 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.825459e-01 | 0.008 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.832762e-01 | 0.007 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.832762e-01 | 0.007 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.832762e-01 | 0.007 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.832762e-01 | 0.007 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.832762e-01 | 0.007 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.834579e-01 | 0.007 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.846283e-01 | 0.007 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.846407e-01 | 0.007 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.847797e-01 | 0.007 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.850898e-01 | 0.007 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.858026e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.858026e-01 | 0.006 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.860615e-01 | 0.006 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.864401e-01 | 0.006 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 9.864713e-01 | 0.006 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.864713e-01 | 0.006 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.867544e-01 | 0.006 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.875268e-01 | 0.005 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.877797e-01 | 0.005 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.879474e-01 | 0.005 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.879474e-01 | 0.005 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.879474e-01 | 0.005 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.880053e-01 | 0.005 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.881010e-01 | 0.005 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.881010e-01 | 0.005 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.882134e-01 | 0.005 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.882134e-01 | 0.005 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.882411e-01 | 0.005 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.889688e-01 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.891772e-01 | 0.005 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.891772e-01 | 0.005 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.895409e-01 | 0.005 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.895678e-01 | 0.005 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.897683e-01 | 0.004 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.897683e-01 | 0.004 | 0 | 0 |
| Free fatty acid receptors | R-HSA-444209 | 9.897683e-01 | 0.004 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.897683e-01 | 0.004 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.899707e-01 | 0.004 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.906137e-01 | 0.004 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.906137e-01 | 0.004 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.906958e-01 | 0.004 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.908121e-01 | 0.004 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.913142e-01 | 0.004 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.913142e-01 | 0.004 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.913142e-01 | 0.004 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.913142e-01 | 0.004 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.913142e-01 | 0.004 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.918047e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.918634e-01 | 0.004 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.918634e-01 | 0.004 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.918634e-01 | 0.004 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.918634e-01 | 0.004 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.919335e-01 | 0.004 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.921359e-01 | 0.003 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.926266e-01 | 0.003 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.926266e-01 | 0.003 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.926266e-01 | 0.003 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.926266e-01 | 0.003 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.929497e-01 | 0.003 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.929497e-01 | 0.003 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.929497e-01 | 0.003 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.929497e-01 | 0.003 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.930040e-01 | 0.003 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.937407e-01 | 0.003 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.937663e-01 | 0.003 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.938936e-01 | 0.003 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.938936e-01 | 0.003 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.943194e-01 | 0.002 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.946866e-01 | 0.002 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.946866e-01 | 0.002 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.946866e-01 | 0.002 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.946919e-01 | 0.002 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.947133e-01 | 0.002 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.948543e-01 | 0.002 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.952337e-01 | 0.002 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.952337e-01 | 0.002 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.954248e-01 | 0.002 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.954248e-01 | 0.002 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.954248e-01 | 0.002 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.954896e-01 | 0.002 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.954896e-01 | 0.002 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.955634e-01 | 0.002 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.955634e-01 | 0.002 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.960823e-01 | 0.002 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 9.960929e-01 | 0.002 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.961347e-01 | 0.002 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.961712e-01 | 0.002 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.961712e-01 | 0.002 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.963474e-01 | 0.002 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.963474e-01 | 0.002 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.964348e-01 | 0.002 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.965772e-01 | 0.001 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.965772e-01 | 0.001 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.967190e-01 | 0.001 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.967499e-01 | 0.001 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.967499e-01 | 0.001 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.968349e-01 | 0.001 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.970411e-01 | 0.001 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.970411e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.970411e-01 | 0.001 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.972412e-01 | 0.001 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.972412e-01 | 0.001 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.973107e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.975515e-01 | 0.001 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.976582e-01 | 0.001 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.978873e-01 | 0.001 | 0 | 0 |
| Translation | R-HSA-72766 | 9.979471e-01 | 0.001 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.980122e-01 | 0.001 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.980922e-01 | 0.001 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.980922e-01 | 0.001 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.980922e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.983093e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.983093e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.983093e-01 | 0.001 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.983233e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.983529e-01 | 0.001 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.983529e-01 | 0.001 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.983739e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.983739e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.983824e-01 | 0.001 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.985678e-01 | 0.001 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.985678e-01 | 0.001 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.985678e-01 | 0.001 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.985678e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.987489e-01 | 0.001 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.987624e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.987734e-01 | 0.001 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.987843e-01 | 0.001 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.987843e-01 | 0.001 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.989003e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.989003e-01 | 0.000 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.989210e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.989781e-01 | 0.000 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.990278e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.990595e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.990595e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.991516e-01 | 0.000 | 0 | 0 |
| Ubiquinol biosynthesis | R-HSA-2142789 | 9.992566e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.992566e-01 | 0.000 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.992566e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.992705e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.993467e-01 | 0.000 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.993690e-01 | 0.000 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.993690e-01 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.994966e-01 | 0.000 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.995454e-01 | 0.000 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.995454e-01 | 0.000 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.995454e-01 | 0.000 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.995585e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.995593e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.995802e-01 | 0.000 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.996142e-01 | 0.000 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.996142e-01 | 0.000 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.996142e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.996428e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.996440e-01 | 0.000 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.996726e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.996875e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.996998e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.997038e-01 | 0.000 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.997641e-01 | 0.000 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.997641e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.997700e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.997951e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.997951e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.997971e-01 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.997971e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.997976e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.997998e-01 | 0.000 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.998237e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.998295e-01 | 0.000 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.998558e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.998674e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.998776e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.998859e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.998961e-01 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.999005e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.999037e-01 | 0.000 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.999079e-01 | 0.000 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.999119e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.999229e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999229e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.999229e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.999252e-01 | 0.000 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.999365e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.999365e-01 | 0.000 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.999365e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999389e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999389e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999561e-01 | 0.000 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.999577e-01 | 0.000 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.999612e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999634e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.999667e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.999671e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999721e-01 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.999742e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999772e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.999790e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.999820e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999830e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999832e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999853e-01 | 0.000 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.999867e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999903e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.999909e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999919e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999928e-01 | 0.000 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.999929e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999947e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999952e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999954e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999961e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999971e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999972e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999975e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999976e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.999976e-01 | 0.000 | 0 | 0 |
| Classical antibody-mediated complement activation | R-HSA-173623 | 9.999979e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999983e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999983e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999988e-01 | 0.000 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.999990e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999992e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999994e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999994e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999996e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999997e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999997e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999997e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999998e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999998e-01 | 0.000 | 0 | 0 |
| Creation of C4 and C2 activators | R-HSA-166786 | 9.999999e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 1.000000e+00 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 4.434064e-11 | 10.353 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 9.387658e-10 | 9.027 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.975322e-09 | 8.401 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 8.881799e-09 | 8.051 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 4.280185e-08 | 7.369 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 5.303670e-08 | 7.275 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.180914e-05 | 4.928 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.811595e-05 | 4.742 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.075819e-05 | 4.683 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.075819e-05 | 4.683 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 2.087838e-05 | 4.680 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.943423e-04 | 3.711 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.140552e-04 | 3.669 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.263919e-04 | 3.645 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.402809e-04 | 3.619 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 5.221362e-04 | 3.282 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 4.842023e-04 | 3.315 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 5.941544e-04 | 3.226 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 8.375375e-04 | 3.077 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 9.457331e-04 | 3.024 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 9.513305e-04 | 3.022 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.161504e-03 | 2.935 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.162268e-03 | 2.935 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.178562e-03 | 2.929 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.128559e-03 | 2.947 | 1 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 1.573519e-03 | 2.803 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.840061e-03 | 2.735 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.012653e-03 | 2.696 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.029619e-03 | 2.519 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.376718e-03 | 2.472 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.502166e-03 | 2.347 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.502166e-03 | 2.347 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 4.502166e-03 | 2.347 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.507232e-03 | 2.259 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.518624e-03 | 2.258 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 6.062877e-03 | 2.217 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 7.834878e-03 | 2.106 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.455522e-03 | 2.128 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 7.834878e-03 | 2.106 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 8.062613e-03 | 2.094 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 8.797862e-03 | 2.056 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 8.797862e-03 | 2.056 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.099248e-03 | 2.041 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 9.810991e-03 | 2.008 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.024643e-02 | 1.989 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.081634e-02 | 1.966 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.087339e-02 | 1.964 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.198421e-02 | 1.921 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.181825e-02 | 1.927 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.399839e-02 | 1.854 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 1.417436e-02 | 1.848 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.434770e-02 | 1.843 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.632556e-02 | 1.787 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.691635e-02 | 1.772 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.823517e-02 | 1.739 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.852683e-02 | 1.732 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.884572e-02 | 1.725 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.163369e-02 | 1.665 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.218062e-02 | 1.654 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.251397e-02 | 1.648 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.402355e-02 | 1.619 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.402355e-02 | 1.619 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.429401e-02 | 1.615 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.226113e-02 | 1.491 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 3.226113e-02 | 1.491 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 3.226113e-02 | 1.491 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.226113e-02 | 1.491 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.226113e-02 | 1.491 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.226113e-02 | 1.491 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.226113e-02 | 1.491 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 3.045825e-02 | 1.516 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 2.879160e-02 | 1.541 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 3.045825e-02 | 1.516 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.952341e-02 | 1.530 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 2.879160e-02 | 1.541 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.875690e-02 | 1.541 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.879160e-02 | 1.541 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 2.716311e-02 | 1.566 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 2.771113e-02 | 1.557 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 3.296758e-02 | 1.482 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.300369e-02 | 1.481 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 3.390316e-02 | 1.470 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.749218e-02 | 1.426 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.121980e-02 | 1.385 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 4.121980e-02 | 1.385 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.906825e-02 | 1.408 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.637018e-02 | 1.439 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.019319e-02 | 1.396 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 4.121980e-02 | 1.385 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 4.045544e-02 | 1.393 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.518811e-02 | 1.454 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 4.800219e-02 | 1.319 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 4.800219e-02 | 1.319 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 4.508062e-02 | 1.346 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.800219e-02 | 1.319 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 4.422764e-02 | 1.354 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.800219e-02 | 1.319 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 4.800219e-02 | 1.319 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 4.855721e-02 | 1.314 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.800219e-02 | 1.319 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.111018e-02 | 1.291 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 4.278563e-02 | 1.369 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 4.705934e-02 | 1.327 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 4.962928e-02 | 1.304 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 4.705934e-02 | 1.327 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 4.508062e-02 | 1.346 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.906940e-02 | 1.309 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 5.113946e-02 | 1.291 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 5.318103e-02 | 1.274 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.387577e-02 | 1.269 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.387577e-02 | 1.269 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.528135e-02 | 1.257 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.577717e-02 | 1.254 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.577717e-02 | 1.254 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 5.577717e-02 | 1.254 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.577717e-02 | 1.254 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.741053e-02 | 1.241 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.741053e-02 | 1.241 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.741053e-02 | 1.241 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.348912e-02 | 1.197 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.348912e-02 | 1.197 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.348912e-02 | 1.197 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.113856e-02 | 1.148 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 7.113856e-02 | 1.148 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.872598e-02 | 1.104 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 7.872598e-02 | 1.104 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 6.396518e-02 | 1.194 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.872598e-02 | 1.104 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.075827e-02 | 1.150 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.348912e-02 | 1.197 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.348912e-02 | 1.197 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.348912e-02 | 1.197 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 7.872598e-02 | 1.104 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 7.777455e-02 | 1.109 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.348912e-02 | 1.197 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 7.317192e-02 | 1.136 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.348912e-02 | 1.197 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 6.348912e-02 | 1.197 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.872598e-02 | 1.104 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 7.082721e-02 | 1.150 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 5.985058e-02 | 1.223 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 6.251379e-02 | 1.204 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 6.251379e-02 | 1.204 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 7.777455e-02 | 1.109 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 5.956795e-02 | 1.225 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 8.625190e-02 | 1.064 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 8.625190e-02 | 1.064 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 8.625190e-02 | 1.064 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 8.625190e-02 | 1.064 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 9.371680e-02 | 1.028 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.011212e-01 | 0.995 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.157503e-01 | 0.936 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.229760e-01 | 0.910 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 1.229760e-01 | 0.910 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 1.229760e-01 | 0.910 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 1.301431e-01 | 0.886 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.301431e-01 | 0.886 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.443033e-01 | 0.841 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 1.512974e-01 | 0.820 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 1.512974e-01 | 0.820 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 1.582348e-01 | 0.801 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 1.582348e-01 | 0.801 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 1.651159e-01 | 0.782 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 1.651159e-01 | 0.782 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.787110e-01 | 0.748 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 1.920865e-01 | 0.717 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 1.986929e-01 | 0.702 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.117453e-01 | 0.674 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.117453e-01 | 0.674 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 2.117453e-01 | 0.674 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 2.181921e-01 | 0.661 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 2.309293e-01 | 0.637 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 2.372204e-01 | 0.625 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.372204e-01 | 0.625 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.372204e-01 | 0.625 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.854260e-01 | 0.732 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.443033e-01 | 0.841 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 8.625190e-02 | 1.064 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.833501e-01 | 0.737 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.854260e-01 | 0.732 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.402951e-01 | 0.853 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.309293e-01 | 0.637 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.372204e-01 | 0.625 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.370521e-01 | 0.625 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.117453e-01 | 0.674 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.011212e-01 | 0.995 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.157503e-01 | 0.936 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.157503e-01 | 0.936 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.229760e-01 | 0.910 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 1.719412e-01 | 0.765 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 1.787110e-01 | 0.748 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.997079e-01 | 0.700 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.719412e-01 | 0.765 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 1.986929e-01 | 0.702 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.052457e-01 | 0.688 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 9.371680e-02 | 1.028 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.719412e-01 | 0.765 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.745766e-01 | 0.758 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 2.052457e-01 | 0.688 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 1.920865e-01 | 0.717 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 1.920865e-01 | 0.717 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 2.181921e-01 | 0.661 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 2.245867e-01 | 0.649 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 9.477255e-02 | 1.023 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.181921e-01 | 0.661 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.172564e-01 | 0.931 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.787110e-01 | 0.748 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 2.372204e-01 | 0.625 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.234460e-01 | 0.909 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.180887e-01 | 0.928 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.719412e-01 | 0.765 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 1.084655e-01 | 0.965 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.229760e-01 | 0.910 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.443033e-01 | 0.841 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.181921e-01 | 0.661 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.181921e-01 | 0.661 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.686782e-02 | 1.014 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.686782e-02 | 1.014 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 1.018188e-01 | 0.992 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 1.018188e-01 | 0.992 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.572548e-01 | 0.803 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.327522e-01 | 0.877 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.773198e-01 | 0.751 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.721311e-01 | 0.764 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.647869e-01 | 0.783 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 9.371680e-02 | 1.028 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.512974e-01 | 0.820 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.487249e-01 | 0.828 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 8.879522e-02 | 1.052 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.316653e-01 | 0.881 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.563051e-01 | 0.806 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 1.229760e-01 | 0.910 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.512974e-01 | 0.820 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.719412e-01 | 0.765 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 2.174374e-01 | 0.663 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 9.977106e-02 | 1.001 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.443033e-01 | 0.841 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.409723e-01 | 0.851 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 1.372520e-01 | 0.862 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 1.787110e-01 | 0.748 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.854260e-01 | 0.732 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 1.920865e-01 | 0.717 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.986929e-01 | 0.702 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 2.117453e-01 | 0.674 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 1.375091e-01 | 0.862 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 1.854260e-01 | 0.732 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 1.787110e-01 | 0.748 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 2.245867e-01 | 0.649 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 1.658752e-01 | 0.780 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 1.787110e-01 | 0.748 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 2.245867e-01 | 0.649 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.430933e-01 | 0.844 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.402951e-01 | 0.853 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 1.084655e-01 | 0.965 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.443033e-01 | 0.841 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.787110e-01 | 0.748 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.912086e-02 | 1.004 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.892349e-01 | 0.723 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.459034e-01 | 0.836 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.443033e-01 | 0.841 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.245867e-01 | 0.649 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.245867e-01 | 0.649 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.092491e-01 | 0.679 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 2.309293e-01 | 0.637 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 9.524010e-02 | 1.021 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.719412e-01 | 0.765 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.719412e-01 | 0.765 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.563051e-01 | 0.806 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.629923e-01 | 0.788 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 9.362385e-02 | 1.029 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.459034e-01 | 0.836 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 1.025900e-01 | 0.989 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 1.264956e-01 | 0.898 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 2.245867e-01 | 0.649 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.629923e-01 | 0.788 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.052457e-01 | 0.688 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.745149e-02 | 1.058 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 2.245867e-01 | 0.649 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 1.512974e-01 | 0.820 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 1.512974e-01 | 0.820 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 1.402951e-01 | 0.853 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.402951e-01 | 0.853 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.347358e-01 | 0.871 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.057901e-01 | 0.976 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.181921e-01 | 0.661 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.181921e-01 | 0.661 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.011991e-01 | 0.995 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.745149e-02 | 1.058 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.250054e-01 | 0.648 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.638290e-02 | 1.016 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.250054e-01 | 0.648 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.250054e-01 | 0.648 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.372204e-01 | 0.625 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.051795e-01 | 0.978 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 1.719412e-01 | 0.765 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 2.052457e-01 | 0.688 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 2.250054e-01 | 0.648 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.210727e-01 | 0.917 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 9.686782e-02 | 1.014 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 2.119199e-01 | 0.674 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.256311e-01 | 0.901 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.515576e-01 | 0.819 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.862891e-01 | 0.730 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 2.405666e-01 | 0.619 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.430895e-01 | 0.614 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.430895e-01 | 0.614 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.434605e-01 | 0.614 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.434605e-01 | 0.614 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.434605e-01 | 0.614 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.434605e-01 | 0.614 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 2.434605e-01 | 0.614 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.434605e-01 | 0.614 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 2.479507e-01 | 0.606 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.485028e-01 | 0.605 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 2.491336e-01 | 0.604 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.493775e-01 | 0.603 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.496498e-01 | 0.603 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 2.496498e-01 | 0.603 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.496498e-01 | 0.603 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.496498e-01 | 0.603 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 2.496498e-01 | 0.603 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 2.496498e-01 | 0.603 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.551829e-01 | 0.593 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.551829e-01 | 0.593 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.557890e-01 | 0.592 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 2.557890e-01 | 0.592 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.582088e-01 | 0.588 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.582088e-01 | 0.588 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.610004e-01 | 0.583 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.612353e-01 | 0.583 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 2.642623e-01 | 0.578 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 2.642623e-01 | 0.578 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 2.679181e-01 | 0.572 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.733434e-01 | 0.563 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.739089e-01 | 0.562 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.739089e-01 | 0.562 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.739089e-01 | 0.562 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.763699e-01 | 0.559 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 2.798510e-01 | 0.553 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 2.798510e-01 | 0.553 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.824209e-01 | 0.549 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.857449e-01 | 0.544 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 2.857449e-01 | 0.544 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.857449e-01 | 0.544 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 2.857449e-01 | 0.544 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 2.857449e-01 | 0.544 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 2.857449e-01 | 0.544 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 2.884679e-01 | 0.540 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.973893e-01 | 0.527 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 2.973893e-01 | 0.527 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.973893e-01 | 0.527 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.973893e-01 | 0.527 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.973893e-01 | 0.527 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 2.973893e-01 | 0.527 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 2.973893e-01 | 0.527 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 2.973893e-01 | 0.527 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.031407e-01 | 0.518 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 3.031407e-01 | 0.518 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.035588e-01 | 0.518 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.035588e-01 | 0.518 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.088454e-01 | 0.510 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.101924e-01 | 0.508 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 3.101924e-01 | 0.508 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.145037e-01 | 0.502 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.145037e-01 | 0.502 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 3.145037e-01 | 0.502 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 3.185946e-01 | 0.497 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.201161e-01 | 0.495 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.201161e-01 | 0.495 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.201161e-01 | 0.495 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.201161e-01 | 0.495 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.201161e-01 | 0.495 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.201161e-01 | 0.495 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.201161e-01 | 0.495 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.245889e-01 | 0.489 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.256828e-01 | 0.487 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.256828e-01 | 0.487 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 3.256828e-01 | 0.487 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 3.275813e-01 | 0.485 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 3.283296e-01 | 0.484 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 3.312043e-01 | 0.480 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 3.312043e-01 | 0.480 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 3.312043e-01 | 0.480 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.312043e-01 | 0.480 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.312043e-01 | 0.480 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.312043e-01 | 0.480 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.366809e-01 | 0.473 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.366809e-01 | 0.473 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 3.421130e-01 | 0.466 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 3.475010e-01 | 0.459 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 3.475010e-01 | 0.459 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 3.475010e-01 | 0.459 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.504139e-01 | 0.455 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 3.528452e-01 | 0.452 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 3.528452e-01 | 0.452 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 3.528452e-01 | 0.452 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.546582e-01 | 0.450 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.581459e-01 | 0.446 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.581459e-01 | 0.446 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.581459e-01 | 0.446 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.581459e-01 | 0.446 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.581459e-01 | 0.446 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.581459e-01 | 0.446 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 3.590914e-01 | 0.445 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.634036e-01 | 0.440 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.737910e-01 | 0.427 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.737910e-01 | 0.427 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.737910e-01 | 0.427 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 3.789214e-01 | 0.421 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 3.789214e-01 | 0.421 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 3.789214e-01 | 0.421 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.840101e-01 | 0.416 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 3.840101e-01 | 0.416 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.890575e-01 | 0.410 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 3.890575e-01 | 0.410 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.894219e-01 | 0.410 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 3.923091e-01 | 0.406 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 3.923716e-01 | 0.406 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 3.940638e-01 | 0.404 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.940638e-01 | 0.404 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.940638e-01 | 0.404 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 3.940638e-01 | 0.404 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 3.951903e-01 | 0.403 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 4.039546e-01 | 0.394 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 4.039546e-01 | 0.394 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.088397e-01 | 0.388 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.088397e-01 | 0.388 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 4.088397e-01 | 0.388 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 4.088397e-01 | 0.388 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.123453e-01 | 0.385 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.136851e-01 | 0.383 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.136851e-01 | 0.383 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.136851e-01 | 0.383 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 4.136851e-01 | 0.383 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.136851e-01 | 0.383 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.184911e-01 | 0.378 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.184911e-01 | 0.378 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 4.231092e-01 | 0.374 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.231092e-01 | 0.374 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 4.232580e-01 | 0.373 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 4.232580e-01 | 0.373 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 4.232580e-01 | 0.373 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 4.232580e-01 | 0.373 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.279861e-01 | 0.369 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.279861e-01 | 0.369 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 4.279861e-01 | 0.369 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.292607e-01 | 0.367 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.326757e-01 | 0.364 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 4.326757e-01 | 0.364 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 4.326757e-01 | 0.364 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 4.326757e-01 | 0.364 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.338811e-01 | 0.363 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.373272e-01 | 0.359 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 4.373272e-01 | 0.359 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.373272e-01 | 0.359 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.419408e-01 | 0.355 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.419408e-01 | 0.355 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.419408e-01 | 0.355 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.465169e-01 | 0.350 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.465169e-01 | 0.350 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 4.486329e-01 | 0.348 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.510557e-01 | 0.346 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.510557e-01 | 0.346 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 4.555576e-01 | 0.341 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 4.595963e-01 | 0.338 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 4.600228e-01 | 0.337 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.623084e-01 | 0.335 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.644517e-01 | 0.333 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 4.644517e-01 | 0.333 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 4.644517e-01 | 0.333 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.644517e-01 | 0.333 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 4.677088e-01 | 0.330 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 4.677088e-01 | 0.330 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 4.732017e-01 | 0.325 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.732017e-01 | 0.325 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.732017e-01 | 0.325 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.732017e-01 | 0.325 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.775233e-01 | 0.321 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 4.775233e-01 | 0.321 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 4.775233e-01 | 0.321 | 0 | 0 |
| Disease | R-HSA-1643685 | 4.806270e-01 | 0.318 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 4.818097e-01 | 0.317 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 4.818097e-01 | 0.317 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 4.818097e-01 | 0.317 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.860613e-01 | 0.313 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.860613e-01 | 0.313 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.902782e-01 | 0.310 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 4.902782e-01 | 0.310 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 4.942251e-01 | 0.306 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.944607e-01 | 0.306 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.944607e-01 | 0.306 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 4.944607e-01 | 0.306 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 4.968311e-01 | 0.304 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 4.986093e-01 | 0.302 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 5.020177e-01 | 0.299 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 5.020177e-01 | 0.299 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 5.027240e-01 | 0.299 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 5.068052e-01 | 0.295 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 5.068052e-01 | 0.295 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 5.071702e-01 | 0.295 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.071702e-01 | 0.295 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.148681e-01 | 0.288 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 5.148681e-01 | 0.288 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 5.188504e-01 | 0.285 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 5.199005e-01 | 0.284 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.228002e-01 | 0.282 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 5.267179e-01 | 0.278 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 5.274340e-01 | 0.278 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 5.306036e-01 | 0.275 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.344577e-01 | 0.272 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 5.344577e-01 | 0.272 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 5.458325e-01 | 0.263 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 5.495624e-01 | 0.260 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.495624e-01 | 0.260 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 5.510029e-01 | 0.259 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.532620e-01 | 0.257 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 5.535731e-01 | 0.257 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 5.569314e-01 | 0.254 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.569314e-01 | 0.254 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 5.605709e-01 | 0.251 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 5.677611e-01 | 0.246 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.677611e-01 | 0.246 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 5.712134e-01 | 0.243 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 5.748345e-01 | 0.240 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 5.748345e-01 | 0.240 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 5.779165e-01 | 0.238 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.783280e-01 | 0.238 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 5.802207e-01 | 0.236 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.852298e-01 | 0.233 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 5.886385e-01 | 0.230 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.886385e-01 | 0.230 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 5.920195e-01 | 0.228 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 5.986988e-01 | 0.223 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.019977e-01 | 0.220 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.052696e-01 | 0.218 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 6.052696e-01 | 0.218 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.052696e-01 | 0.218 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 6.071577e-01 | 0.217 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 6.120308e-01 | 0.213 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 6.136858e-01 | 0.212 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 6.149261e-01 | 0.211 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 6.149261e-01 | 0.211 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 6.180926e-01 | 0.209 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 6.222618e-01 | 0.206 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.243482e-01 | 0.205 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.274377e-01 | 0.202 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 6.274377e-01 | 0.202 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 6.425113e-01 | 0.192 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.445864e-01 | 0.191 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 6.483698e-01 | 0.188 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 6.491269e-01 | 0.188 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 6.629601e-01 | 0.179 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 6.668319e-01 | 0.176 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 6.681342e-01 | 0.175 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.708662e-01 | 0.173 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.708662e-01 | 0.173 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.762634e-01 | 0.170 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 6.762634e-01 | 0.170 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.763558e-01 | 0.170 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 6.893751e-01 | 0.162 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.068507e-01 | 0.151 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.105560e-01 | 0.148 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 7.187323e-01 | 0.143 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 7.202427e-01 | 0.143 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.256306e-01 | 0.139 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.256306e-01 | 0.139 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.256306e-01 | 0.139 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 7.278925e-01 | 0.138 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 7.321908e-01 | 0.135 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.323610e-01 | 0.135 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.323610e-01 | 0.135 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 7.367566e-01 | 0.133 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 7.369860e-01 | 0.133 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 7.471261e-01 | 0.127 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.474347e-01 | 0.126 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.495181e-01 | 0.125 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 7.495181e-01 | 0.125 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.536340e-01 | 0.123 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 7.536340e-01 | 0.123 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 7.556667e-01 | 0.122 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 7.596823e-01 | 0.119 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 7.636324e-01 | 0.117 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 7.655832e-01 | 0.116 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 7.694370e-01 | 0.114 | 1 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 7.769570e-01 | 0.110 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 7.824368e-01 | 0.107 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 7.852546e-01 | 0.105 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.943051e-01 | 0.100 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.964050e-01 | 0.099 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.980873e-01 | 0.098 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 8.046793e-01 | 0.094 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.202398e-01 | 0.086 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 8.208503e-01 | 0.086 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.217265e-01 | 0.085 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 8.261137e-01 | 0.083 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 8.372961e-01 | 0.077 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.399783e-01 | 0.076 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 8.399783e-01 | 0.076 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 8.516763e-01 | 0.070 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 8.527451e-01 | 0.069 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 8.527451e-01 | 0.069 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 8.568971e-01 | 0.067 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 8.599144e-01 | 0.066 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 8.603289e-01 | 0.065 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 8.700239e-01 | 0.060 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 8.732301e-01 | 0.059 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 8.773833e-01 | 0.057 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 8.804093e-01 | 0.055 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 8.847330e-01 | 0.053 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 8.899707e-01 | 0.051 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.045151e-01 | 0.044 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.171495e-01 | 0.038 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.171495e-01 | 0.038 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 9.402091e-01 | 0.027 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.621220e-01 | 0.017 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.714438e-01 | 0.013 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.714438e-01 | 0.013 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.809505e-01 | 0.008 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.953749e-01 | 0.002 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.997353e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.997551e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999710e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 3.885781e-15 | 14.411 | 0 | 0 |
| M Phase | R-HSA-68886 | 5.218048e-15 | 14.282 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 6.994405e-15 | 14.155 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.309264e-14 | 13.637 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.264855e-14 | 13.645 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.560485e-13 | 12.448 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.791345e-12 | 11.747 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.997314e-12 | 11.222 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.601308e-11 | 10.337 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 5.531509e-11 | 10.257 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.723406e-10 | 9.565 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 8.574336e-10 | 9.067 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.413658e-09 | 8.850 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 9.818290e-09 | 8.008 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 9.649919e-09 | 8.015 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.510069e-08 | 7.821 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.510069e-08 | 7.821 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.663323e-08 | 7.779 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.764154e-08 | 7.558 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 4.114420e-08 | 7.386 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 6.694147e-08 | 7.174 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.845827e-08 | 7.165 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 7.230626e-08 | 7.141 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 9.369353e-08 | 7.028 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 9.487417e-08 | 7.023 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.180254e-07 | 6.928 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.810758e-07 | 6.742 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.952006e-07 | 6.710 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.207557e-07 | 6.656 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.873077e-07 | 6.542 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 4.011025e-07 | 6.397 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.408260e-07 | 6.356 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.366176e-07 | 6.360 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 5.074813e-07 | 6.295 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 5.592349e-07 | 6.252 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.592414e-07 | 6.252 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 7.949780e-07 | 6.100 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 7.840010e-07 | 6.106 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 8.938424e-07 | 6.049 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 8.834694e-07 | 6.054 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.035815e-06 | 5.985 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.057107e-06 | 5.976 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.186342e-06 | 5.926 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.186342e-06 | 5.926 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.284807e-06 | 5.891 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.295814e-06 | 5.887 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.329006e-06 | 5.876 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.414327e-06 | 5.849 | 1 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.479757e-06 | 5.830 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.767528e-06 | 5.753 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.655315e-06 | 5.437 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.108668e-06 | 5.386 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.520600e-06 | 5.345 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 4.651109e-06 | 5.332 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 5.683020e-06 | 5.245 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.410349e-06 | 5.193 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.265348e-06 | 5.203 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 7.888003e-06 | 5.103 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 7.482221e-06 | 5.126 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 7.861384e-06 | 5.105 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 7.746367e-06 | 5.111 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 8.451099e-06 | 5.073 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 8.892299e-06 | 5.051 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 9.308284e-06 | 5.031 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.145701e-05 | 4.941 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.185871e-05 | 4.926 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.280238e-05 | 4.893 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.406105e-05 | 4.852 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.521622e-05 | 4.818 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.720159e-05 | 4.764 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.746607e-05 | 4.758 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.050337e-05 | 4.688 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.082236e-05 | 4.681 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.586804e-05 | 4.587 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.586804e-05 | 4.587 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.586804e-05 | 4.587 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.586804e-05 | 4.587 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.586804e-05 | 4.587 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.385732e-05 | 4.622 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.385732e-05 | 4.622 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 2.593485e-05 | 4.586 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.929429e-05 | 4.533 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 3.138904e-05 | 4.503 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.361930e-05 | 4.473 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.754985e-05 | 4.425 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.943419e-05 | 4.404 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 4.140678e-05 | 4.383 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.390804e-05 | 4.357 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 4.623249e-05 | 4.335 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 5.098257e-05 | 4.293 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 5.058246e-05 | 4.296 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.154182e-05 | 4.288 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.417397e-05 | 4.266 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 5.520485e-05 | 4.258 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 5.960875e-05 | 4.225 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 5.960875e-05 | 4.225 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 6.102201e-05 | 4.215 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 6.268217e-05 | 4.203 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 6.352592e-05 | 4.197 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 6.352592e-05 | 4.197 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 6.353172e-05 | 4.197 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.849406e-05 | 4.164 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 6.559854e-05 | 4.183 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 6.642130e-05 | 4.178 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 7.163950e-05 | 4.145 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.426014e-05 | 4.129 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.426014e-05 | 4.129 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.782718e-05 | 4.109 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 7.870221e-05 | 4.104 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.996134e-05 | 4.097 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 8.573772e-05 | 4.067 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 1.032391e-04 | 3.986 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.112037e-04 | 3.954 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.135739e-04 | 3.945 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.138176e-04 | 3.944 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.162467e-04 | 3.935 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.360338e-04 | 3.866 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.360338e-04 | 3.866 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.400556e-04 | 3.854 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.510084e-04 | 3.821 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.566770e-04 | 3.805 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.646834e-04 | 3.783 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.648070e-04 | 3.783 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.601655e-04 | 3.795 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.687552e-04 | 3.773 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.692209e-04 | 3.772 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.933418e-04 | 3.714 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.935453e-04 | 3.713 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.996667e-04 | 3.700 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.110476e-04 | 3.676 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.154687e-04 | 3.667 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.160088e-04 | 3.666 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 2.256188e-04 | 3.647 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.275104e-04 | 3.643 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 2.296143e-04 | 3.639 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.624411e-04 | 3.581 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.602303e-04 | 3.585 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.668730e-04 | 3.574 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.695340e-04 | 3.569 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.927712e-04 | 3.533 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.992164e-04 | 3.524 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.992164e-04 | 3.524 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 3.102467e-04 | 3.508 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.418681e-04 | 3.466 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.313414e-04 | 3.480 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.418681e-04 | 3.466 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.190690e-04 | 3.496 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.145549e-04 | 3.502 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 3.418681e-04 | 3.466 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.152325e-04 | 3.501 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 3.158900e-04 | 3.500 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.614293e-04 | 3.442 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.643283e-04 | 3.439 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.867422e-04 | 3.413 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.924304e-04 | 3.406 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.284255e-04 | 3.368 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.399391e-04 | 3.357 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 4.475348e-04 | 3.349 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.483863e-04 | 3.348 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 4.614562e-04 | 3.336 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.614562e-04 | 3.336 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.063083e-04 | 3.296 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 5.252097e-04 | 3.280 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 5.654373e-04 | 3.248 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 5.786464e-04 | 3.238 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.216036e-04 | 3.206 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 6.385127e-04 | 3.195 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 6.430929e-04 | 3.192 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.460366e-04 | 3.190 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.542450e-04 | 3.184 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 6.544854e-04 | 3.184 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.563588e-04 | 3.183 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 6.891102e-04 | 3.162 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 6.891102e-04 | 3.162 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 7.752652e-04 | 3.111 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.321358e-04 | 3.135 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.554106e-04 | 3.122 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 7.554106e-04 | 3.122 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 7.008744e-04 | 3.154 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.008744e-04 | 3.154 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 7.168898e-04 | 3.145 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 7.822064e-04 | 3.107 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 8.095282e-04 | 3.092 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 8.095282e-04 | 3.092 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 8.137637e-04 | 3.090 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 8.164115e-04 | 3.088 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 8.164115e-04 | 3.088 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 8.297655e-04 | 3.081 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 8.454839e-04 | 3.073 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 8.514902e-04 | 3.070 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 8.968557e-04 | 3.047 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.132602e-04 | 3.039 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 9.132602e-04 | 3.039 | 0 | 0 |
| S Phase | R-HSA-69242 | 9.148246e-04 | 3.039 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.157605e-04 | 3.038 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 9.607975e-04 | 3.017 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 9.704315e-04 | 3.013 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.027772e-03 | 2.988 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.068989e-03 | 2.971 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.098558e-03 | 2.959 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.133977e-03 | 2.945 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 1.133977e-03 | 2.945 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 1.198556e-03 | 2.921 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.214558e-03 | 2.916 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 1.215990e-03 | 2.915 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.251672e-03 | 2.903 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 1.283535e-03 | 2.892 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.283535e-03 | 2.892 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.298080e-03 | 2.887 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.315043e-03 | 2.881 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 1.322456e-03 | 2.879 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.367862e-03 | 2.864 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.371429e-03 | 2.863 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.394614e-03 | 2.856 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.394614e-03 | 2.856 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.424141e-03 | 2.846 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 1.440528e-03 | 2.841 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.446988e-03 | 2.840 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.536989e-03 | 2.813 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.598823e-03 | 2.796 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.566800e-03 | 2.805 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.555396e-03 | 2.808 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.771492e-03 | 2.752 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.748168e-03 | 2.757 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.692785e-03 | 2.771 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.578919e-03 | 2.802 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.783486e-03 | 2.749 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.783486e-03 | 2.749 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.801769e-03 | 2.744 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 1.801769e-03 | 2.744 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 1.957152e-03 | 2.708 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.957152e-03 | 2.708 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 2.022136e-03 | 2.694 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 2.022136e-03 | 2.694 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.068800e-03 | 2.684 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 2.068800e-03 | 2.684 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.169534e-03 | 2.664 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.169534e-03 | 2.664 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.181920e-03 | 2.661 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.181920e-03 | 2.661 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.220229e-03 | 2.654 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.235177e-03 | 2.651 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.235177e-03 | 2.651 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.241722e-03 | 2.649 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.241722e-03 | 2.649 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.242574e-03 | 2.649 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.268144e-03 | 2.644 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 2.317900e-03 | 2.635 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.391215e-03 | 2.621 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.391215e-03 | 2.621 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.391215e-03 | 2.621 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.616276e-03 | 2.582 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.684790e-03 | 2.571 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.146632e-03 | 2.502 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.902108e-03 | 2.537 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.902108e-03 | 2.537 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.718241e-03 | 2.566 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.751258e-03 | 2.560 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 2.902108e-03 | 2.537 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 2.751258e-03 | 2.560 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 2.995524e-03 | 2.524 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.969905e-03 | 2.527 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 2.902108e-03 | 2.537 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 3.233813e-03 | 2.490 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.280351e-03 | 2.484 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 3.346137e-03 | 2.475 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 3.346137e-03 | 2.475 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.346137e-03 | 2.475 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.361374e-03 | 2.473 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.383185e-03 | 2.471 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 3.467467e-03 | 2.460 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.509675e-03 | 2.455 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 3.536158e-03 | 2.451 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.576078e-03 | 2.447 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 3.596072e-03 | 2.444 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 3.630870e-03 | 2.440 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.719424e-03 | 2.430 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 3.850557e-03 | 2.414 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.850557e-03 | 2.414 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.875127e-03 | 2.412 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.969616e-03 | 2.401 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 4.077719e-03 | 2.390 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 4.087514e-03 | 2.389 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 4.231368e-03 | 2.374 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.232396e-03 | 2.373 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 4.288399e-03 | 2.368 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.288399e-03 | 2.368 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.421150e-03 | 2.354 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 4.439511e-03 | 2.353 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.439511e-03 | 2.353 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.583407e-03 | 2.339 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 4.734328e-03 | 2.325 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 4.734328e-03 | 2.325 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.736183e-03 | 2.325 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.736183e-03 | 2.325 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 4.760797e-03 | 2.322 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.781324e-03 | 2.320 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 4.819043e-03 | 2.317 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.913283e-03 | 2.309 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 4.913283e-03 | 2.309 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.982825e-03 | 2.303 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.470483e-03 | 2.262 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 5.638430e-03 | 2.249 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 5.638430e-03 | 2.249 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 5.921644e-03 | 2.228 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 5.921644e-03 | 2.228 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.997935e-03 | 2.301 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.566985e-03 | 2.254 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.882475e-03 | 2.230 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.882475e-03 | 2.230 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 5.749207e-03 | 2.240 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 5.881801e-03 | 2.230 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.237877e-03 | 2.205 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 6.279781e-03 | 2.202 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.316650e-03 | 2.200 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 6.683102e-03 | 2.175 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.689802e-03 | 2.175 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.689802e-03 | 2.175 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 6.854943e-03 | 2.164 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 6.854943e-03 | 2.164 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 6.909923e-03 | 2.161 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.909923e-03 | 2.161 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 6.978130e-03 | 2.156 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 6.978130e-03 | 2.156 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 7.142291e-03 | 2.146 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 7.142291e-03 | 2.146 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.317939e-03 | 2.136 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.617676e-03 | 2.118 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 7.617676e-03 | 2.118 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 7.883227e-03 | 2.103 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 8.013679e-03 | 2.096 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.098258e-03 | 2.092 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.098258e-03 | 2.092 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 8.098258e-03 | 2.092 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 8.151845e-03 | 2.089 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 8.260820e-03 | 2.083 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 8.275998e-03 | 2.082 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 8.358914e-03 | 2.078 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 8.764638e-03 | 2.057 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 8.910102e-03 | 2.050 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 8.910102e-03 | 2.050 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 9.078069e-03 | 2.042 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 9.271292e-03 | 2.033 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.323092e-03 | 2.030 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 9.339885e-03 | 2.030 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 9.339885e-03 | 2.030 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 9.339885e-03 | 2.030 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 9.351222e-03 | 2.029 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 9.351222e-03 | 2.029 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 9.458965e-03 | 2.024 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 9.553699e-03 | 2.020 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 9.801094e-03 | 2.009 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.138539e-02 | 1.944 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.138539e-02 | 1.944 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.015005e-02 | 1.994 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 9.988493e-03 | 2.001 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.005331e-02 | 1.998 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.194632e-02 | 1.923 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.063025e-02 | 1.973 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.211371e-02 | 1.917 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.245457e-02 | 1.905 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.194632e-02 | 1.923 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.116699e-02 | 1.952 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.190165e-02 | 1.924 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.148340e-02 | 1.940 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.145370e-02 | 1.941 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.138250e-02 | 1.944 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.228450e-02 | 1.911 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.156228e-02 | 1.937 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.229988e-02 | 1.910 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.140625e-02 | 1.943 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.246935e-02 | 1.904 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.247676e-02 | 1.904 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.247676e-02 | 1.904 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.247676e-02 | 1.904 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.264457e-02 | 1.898 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.268880e-02 | 1.897 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 1.268880e-02 | 1.897 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 1.280139e-02 | 1.893 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.330321e-02 | 1.876 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.332867e-02 | 1.875 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.342848e-02 | 1.872 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.346127e-02 | 1.871 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.358563e-02 | 1.867 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.405421e-02 | 1.852 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.448306e-02 | 1.839 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.459198e-02 | 1.836 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.461523e-02 | 1.835 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.484491e-02 | 1.828 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.493354e-02 | 1.826 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.512383e-02 | 1.820 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 1.515780e-02 | 1.819 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.533030e-02 | 1.814 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.533030e-02 | 1.814 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.545833e-02 | 1.811 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.567154e-02 | 1.805 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 1.584792e-02 | 1.800 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.584792e-02 | 1.800 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.601623e-02 | 1.795 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.623783e-02 | 1.789 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.623783e-02 | 1.789 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 1.638832e-02 | 1.785 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.640980e-02 | 1.785 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.685915e-02 | 1.773 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.685915e-02 | 1.773 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.694318e-02 | 1.771 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 1.694833e-02 | 1.771 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.771644e-02 | 1.752 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.771644e-02 | 1.752 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.771644e-02 | 1.752 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.771644e-02 | 1.752 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.803086e-02 | 1.744 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.803086e-02 | 1.744 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.815174e-02 | 1.741 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 1.820452e-02 | 1.740 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.838591e-02 | 1.736 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.856272e-02 | 1.731 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 2.447277e-02 | 1.611 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.447277e-02 | 1.611 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.500970e-02 | 1.602 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.326505e-02 | 1.633 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 2.326505e-02 | 1.633 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.313057e-02 | 1.636 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.265082e-02 | 1.645 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.307479e-02 | 1.637 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.121869e-02 | 1.673 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.183733e-02 | 1.661 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.938214e-02 | 1.713 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.009005e-02 | 1.697 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.961930e-02 | 1.707 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 2.500970e-02 | 1.602 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.154312e-02 | 1.667 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.326505e-02 | 1.633 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 2.326505e-02 | 1.633 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.326505e-02 | 1.633 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.265082e-02 | 1.645 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 2.076985e-02 | 1.683 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.108922e-02 | 1.676 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.313057e-02 | 1.636 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 2.207946e-02 | 1.656 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 2.316311e-02 | 1.635 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.500970e-02 | 1.602 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 2.175807e-02 | 1.662 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 2.430336e-02 | 1.614 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 2.244198e-02 | 1.649 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.365091e-02 | 1.626 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 1.945630e-02 | 1.711 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.898334e-02 | 1.722 | 0 | 0 |
| Depurination | R-HSA-73927 | 2.207946e-02 | 1.656 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 2.447277e-02 | 1.611 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.447277e-02 | 1.611 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 2.447277e-02 | 1.611 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.121869e-02 | 1.673 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.121869e-02 | 1.673 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 2.543667e-02 | 1.595 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 2.559638e-02 | 1.592 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.565395e-02 | 1.591 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.611385e-02 | 1.583 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.627837e-02 | 1.580 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.655401e-02 | 1.576 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.681215e-02 | 1.572 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.702957e-02 | 1.568 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.740091e-02 | 1.562 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.740091e-02 | 1.562 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.768328e-02 | 1.558 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.768328e-02 | 1.558 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.768328e-02 | 1.558 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.776367e-02 | 1.557 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.845534e-02 | 1.546 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 2.997616e-02 | 1.523 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.997616e-02 | 1.523 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 2.997616e-02 | 1.523 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.997616e-02 | 1.523 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 3.020237e-02 | 1.520 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 3.065487e-02 | 1.514 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 3.078176e-02 | 1.512 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 3.078176e-02 | 1.512 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 3.122929e-02 | 1.505 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.129547e-02 | 1.505 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 3.136680e-02 | 1.504 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.167089e-02 | 1.499 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.167089e-02 | 1.499 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 3.167089e-02 | 1.499 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.198827e-02 | 1.495 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.198827e-02 | 1.495 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.248014e-02 | 1.488 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.253980e-02 | 1.488 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.283158e-02 | 1.484 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 3.307138e-02 | 1.481 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 3.351741e-02 | 1.475 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 3.351741e-02 | 1.475 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 3.351741e-02 | 1.475 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.351741e-02 | 1.475 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 3.351741e-02 | 1.475 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 3.351741e-02 | 1.475 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.351741e-02 | 1.475 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 3.353710e-02 | 1.474 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.539766e-02 | 1.451 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 3.546829e-02 | 1.450 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 3.546829e-02 | 1.450 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.586480e-02 | 1.445 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.586480e-02 | 1.445 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.620102e-02 | 1.441 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.634245e-02 | 1.440 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.718697e-02 | 1.430 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.767346e-02 | 1.424 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.767346e-02 | 1.424 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 3.784313e-02 | 1.422 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.824770e-02 | 1.417 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.855055e-02 | 1.414 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 3.860662e-02 | 1.413 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.860662e-02 | 1.413 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 3.945418e-02 | 1.404 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.945418e-02 | 1.404 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.949115e-02 | 1.404 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 3.991948e-02 | 1.399 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 4.151742e-02 | 1.382 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 4.333205e-02 | 1.363 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.362665e-02 | 1.360 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.362665e-02 | 1.360 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.503578e-02 | 1.346 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.503578e-02 | 1.346 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 4.669224e-02 | 1.331 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.691567e-02 | 1.329 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 4.691567e-02 | 1.329 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 4.753709e-02 | 1.323 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.814947e-02 | 1.317 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 4.859668e-02 | 1.313 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 4.879389e-02 | 1.312 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 6.318959e-02 | 1.199 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 6.318959e-02 | 1.199 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 6.318959e-02 | 1.199 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 6.318959e-02 | 1.199 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 6.318959e-02 | 1.199 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 4.917078e-02 | 1.308 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 7.088862e-02 | 1.149 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 7.088862e-02 | 1.149 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 7.088862e-02 | 1.149 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 7.088862e-02 | 1.149 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 7.088862e-02 | 1.149 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 6.422564e-02 | 1.192 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 6.422564e-02 | 1.192 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 5.537797e-02 | 1.257 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 5.537797e-02 | 1.257 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 6.878046e-02 | 1.163 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 6.878046e-02 | 1.163 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 5.722675e-02 | 1.242 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 6.879229e-02 | 1.162 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.879229e-02 | 1.162 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 5.660353e-02 | 1.247 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 5.660353e-02 | 1.247 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 5.470040e-02 | 1.262 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 5.214228e-02 | 1.283 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.214228e-02 | 1.283 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.214228e-02 | 1.283 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 4.927568e-02 | 1.307 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 5.994480e-02 | 1.222 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.919226e-02 | 1.228 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 6.315680e-02 | 1.200 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.994480e-02 | 1.222 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.781292e-02 | 1.238 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.537797e-02 | 1.257 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 6.644549e-02 | 1.178 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.781292e-02 | 1.238 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.190372e-02 | 1.143 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 5.257669e-02 | 1.279 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.486677e-02 | 1.261 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 6.878046e-02 | 1.163 | 0 | 0 |
| Translation | R-HSA-72766 | 6.921564e-02 | 1.160 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 5.918927e-02 | 1.228 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.320021e-02 | 1.274 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 7.197001e-02 | 1.143 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 6.879229e-02 | 1.162 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 7.320722e-02 | 1.135 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 6.878046e-02 | 1.163 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 6.878046e-02 | 1.163 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 6.878046e-02 | 1.163 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 6.878046e-02 | 1.163 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.509618e-02 | 1.259 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.620457e-02 | 1.250 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.613879e-02 | 1.180 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.422564e-02 | 1.192 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 5.537797e-02 | 1.257 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 6.878046e-02 | 1.163 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 6.878046e-02 | 1.163 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.320021e-02 | 1.274 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 5.248101e-02 | 1.280 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 5.746773e-02 | 1.241 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.628127e-02 | 1.179 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.905892e-02 | 1.229 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 7.320722e-02 | 1.135 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 5.537797e-02 | 1.257 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.220822e-02 | 1.282 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 6.878046e-02 | 1.163 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 6.878046e-02 | 1.163 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 5.408682e-02 | 1.267 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 5.248101e-02 | 1.280 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.761901e-02 | 1.170 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 6.388877e-02 | 1.195 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 5.286451e-02 | 1.277 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 6.422564e-02 | 1.192 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 7.424977e-02 | 1.129 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.775039e-02 | 1.109 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 7.775039e-02 | 1.109 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 7.775039e-02 | 1.109 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 7.781667e-02 | 1.109 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 7.901707e-02 | 1.102 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 8.069209e-02 | 1.093 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.153137e-02 | 1.089 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 8.153137e-02 | 1.089 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.161137e-02 | 1.088 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 8.216006e-02 | 1.085 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 8.216006e-02 | 1.085 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.248005e-02 | 1.084 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 8.261126e-02 | 1.083 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 8.330822e-02 | 1.079 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 8.330822e-02 | 1.079 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.372300e-02 | 1.077 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 8.372300e-02 | 1.077 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 8.381351e-02 | 1.077 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.381351e-02 | 1.077 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 8.421953e-02 | 1.075 | 0 | 0 |
| Kinesins | R-HSA-983189 | 8.424962e-02 | 1.074 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.764269e-02 | 1.057 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 8.764269e-02 | 1.057 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 8.764269e-02 | 1.057 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 8.764269e-02 | 1.057 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 8.838805e-02 | 1.054 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 9.189080e-02 | 1.037 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 9.189080e-02 | 1.037 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.445738e-02 | 1.025 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.566691e-02 | 1.019 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.606190e-02 | 1.017 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 9.606190e-02 | 1.017 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 9.614442e-02 | 1.017 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 9.614442e-02 | 1.017 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 9.940418e-02 | 1.003 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 9.995042e-02 | 1.000 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 1.001634e-01 | 0.999 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.004293e-01 | 0.998 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.004293e-01 | 0.998 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.007466e-01 | 0.997 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.022774e-01 | 0.990 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.022774e-01 | 0.990 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.022774e-01 | 0.990 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.022774e-01 | 0.990 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 1.029171e-01 | 0.988 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 1.030265e-01 | 0.987 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.030265e-01 | 0.987 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.030265e-01 | 0.987 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 1.030265e-01 | 0.987 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 1.030265e-01 | 0.987 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.033235e-01 | 0.986 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.039818e-01 | 0.983 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.057716e-01 | 0.976 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 1.072690e-01 | 0.970 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.072690e-01 | 0.970 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.082232e-01 | 0.966 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.097089e-01 | 0.960 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.097089e-01 | 0.960 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.108853e-01 | 0.955 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.109266e-01 | 0.955 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.109266e-01 | 0.955 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 1.109266e-01 | 0.955 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.109266e-01 | 0.955 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.110564e-01 | 0.954 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.150867e-01 | 0.939 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.150867e-01 | 0.939 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.153386e-01 | 0.938 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.162536e-01 | 0.935 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.169703e-01 | 0.932 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 1.169703e-01 | 0.932 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.185559e-01 | 0.926 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.185559e-01 | 0.926 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 1.185559e-01 | 0.926 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.185559e-01 | 0.926 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 1.189302e-01 | 0.925 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 1.201023e-01 | 0.920 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.202744e-01 | 0.920 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.202744e-01 | 0.920 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.221385e-01 | 0.913 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.244132e-01 | 0.905 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.244132e-01 | 0.905 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.244808e-01 | 0.905 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 1.244808e-01 | 0.905 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 1.244808e-01 | 0.905 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.244808e-01 | 0.905 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.260395e-01 | 0.899 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.266184e-01 | 0.898 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.266184e-01 | 0.898 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.266184e-01 | 0.898 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.266184e-01 | 0.898 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.266184e-01 | 0.898 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.266184e-01 | 0.898 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.266184e-01 | 0.898 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.266184e-01 | 0.898 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.266184e-01 | 0.898 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.266184e-01 | 0.898 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.266184e-01 | 0.898 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.266184e-01 | 0.898 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.266184e-01 | 0.898 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 1.266184e-01 | 0.898 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.266184e-01 | 0.898 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.266184e-01 | 0.898 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.266184e-01 | 0.898 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.266184e-01 | 0.898 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.266184e-01 | 0.898 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.266184e-01 | 0.898 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.266184e-01 | 0.898 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.266184e-01 | 0.898 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.266184e-01 | 0.898 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.266184e-01 | 0.898 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.266184e-01 | 0.898 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.266184e-01 | 0.898 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.266184e-01 | 0.898 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.266184e-01 | 0.898 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.266184e-01 | 0.898 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.266184e-01 | 0.898 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.272165e-01 | 0.895 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.273440e-01 | 0.895 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.273440e-01 | 0.895 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.273440e-01 | 0.895 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.273440e-01 | 0.895 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.273440e-01 | 0.895 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.372110e-01 | 0.625 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.372110e-01 | 0.625 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.372110e-01 | 0.625 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.372110e-01 | 0.625 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 2.372110e-01 | 0.625 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 2.372110e-01 | 0.625 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.372110e-01 | 0.625 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH3 | R-HSA-5632927 | 2.372110e-01 | 0.625 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 1.477964e-01 | 0.830 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.477964e-01 | 0.830 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 1.477964e-01 | 0.830 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.477964e-01 | 0.830 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.477964e-01 | 0.830 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 1.956128e-01 | 0.709 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 1.956128e-01 | 0.709 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.554001e-01 | 0.809 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 1.554001e-01 | 0.809 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.554001e-01 | 0.809 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.449873e-01 | 0.611 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.449873e-01 | 0.611 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.449873e-01 | 0.611 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.883943e-01 | 0.725 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 1.883943e-01 | 0.725 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.883943e-01 | 0.725 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.883943e-01 | 0.725 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.883943e-01 | 0.725 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.483715e-01 | 0.829 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.483715e-01 | 0.829 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.483715e-01 | 0.829 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.483715e-01 | 0.829 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.381007e-01 | 0.860 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.739342e-01 | 0.760 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.739342e-01 | 0.760 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.739342e-01 | 0.760 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.739342e-01 | 0.760 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.739342e-01 | 0.760 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.739342e-01 | 0.760 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 2.229664e-01 | 0.652 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 2.229664e-01 | 0.652 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 2.229664e-01 | 0.652 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 2.229664e-01 | 0.652 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 2.229664e-01 | 0.652 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 2.229664e-01 | 0.652 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.589538e-01 | 0.799 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.008696e-01 | 0.697 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.586461e-01 | 0.587 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 2.586461e-01 | 0.587 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 2.586461e-01 | 0.587 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.809917e-01 | 0.742 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.634061e-01 | 0.787 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.634061e-01 | 0.787 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 2.289397e-01 | 0.640 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 1.829019e-01 | 0.738 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.579065e-01 | 0.589 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 2.579065e-01 | 0.589 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.280805e-01 | 0.642 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.821550e-01 | 0.740 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.799243e-01 | 0.745 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.004412e-01 | 0.698 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.004412e-01 | 0.698 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.965624e-01 | 0.706 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.461974e-01 | 0.609 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.652644e-01 | 0.782 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.961044e-01 | 0.708 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 2.451549e-01 | 0.611 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.355384e-01 | 0.628 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.639352e-01 | 0.785 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.582965e-01 | 0.588 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.759068e-01 | 0.755 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.480346e-01 | 0.830 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 2.004412e-01 | 0.698 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 2.194016e-01 | 0.659 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.394748e-01 | 0.856 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 1.965624e-01 | 0.706 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 1.860376e-01 | 0.730 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 2.406147e-01 | 0.619 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 2.289397e-01 | 0.640 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.310376e-01 | 0.883 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.271618e-01 | 0.644 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.922668e-01 | 0.716 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 1.799243e-01 | 0.745 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.970063e-01 | 0.706 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 1.319644e-01 | 0.880 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.639352e-01 | 0.785 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.739342e-01 | 0.760 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 1.846597e-01 | 0.734 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 2.040808e-01 | 0.690 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.921141e-01 | 0.716 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 2.326711e-01 | 0.633 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 2.586461e-01 | 0.587 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.478594e-01 | 0.830 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.739342e-01 | 0.760 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.965624e-01 | 0.706 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.414219e-01 | 0.617 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.171244e-01 | 0.663 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 1.567426e-01 | 0.805 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 2.202044e-01 | 0.657 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 2.449873e-01 | 0.611 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.483715e-01 | 0.829 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.340737e-01 | 0.873 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.032614e-01 | 0.692 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.032614e-01 | 0.692 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 2.389673e-01 | 0.622 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.580577e-01 | 0.801 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 1.650169e-01 | 0.782 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 2.445183e-01 | 0.612 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.739342e-01 | 0.760 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.319644e-01 | 0.880 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.464674e-01 | 0.834 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.708233e-01 | 0.767 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.956128e-01 | 0.709 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.449873e-01 | 0.611 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.229664e-01 | 0.652 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 1.589538e-01 | 0.799 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 2.586461e-01 | 0.587 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 2.280805e-01 | 0.642 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.639352e-01 | 0.785 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.528464e-01 | 0.597 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.873703e-01 | 0.727 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.170112e-01 | 0.664 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.170112e-01 | 0.664 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.170112e-01 | 0.664 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.170112e-01 | 0.664 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 2.247885e-01 | 0.648 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.416897e-01 | 0.849 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.378383e-01 | 0.861 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.353223e-01 | 0.869 | 1 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.914568e-01 | 0.718 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 2.247885e-01 | 0.648 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 1.759068e-01 | 0.755 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.268859e-01 | 0.644 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.138019e-01 | 0.670 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 2.229664e-01 | 0.652 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 2.528464e-01 | 0.597 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.961044e-01 | 0.708 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.326711e-01 | 0.633 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.630030e-01 | 0.788 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.937421e-01 | 0.713 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.311702e-01 | 0.882 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.630030e-01 | 0.788 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.630030e-01 | 0.788 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.280805e-01 | 0.642 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.314646e-01 | 0.881 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 2.579065e-01 | 0.589 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.528539e-01 | 0.816 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 2.586461e-01 | 0.587 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.567326e-01 | 0.591 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 2.389673e-01 | 0.622 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 1.577589e-01 | 0.802 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.732254e-01 | 0.761 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.372110e-01 | 0.625 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.477964e-01 | 0.830 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.956128e-01 | 0.709 | 0 | 0 |
| RSK activation | R-HSA-444257 | 1.883943e-01 | 0.725 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 2.586461e-01 | 0.587 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.809917e-01 | 0.742 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.032614e-01 | 0.692 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.965624e-01 | 0.706 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.170112e-01 | 0.664 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.634061e-01 | 0.787 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.362235e-01 | 0.866 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 1.907788e-01 | 0.719 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.821550e-01 | 0.740 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 2.289397e-01 | 0.640 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.646077e-01 | 0.784 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.138019e-01 | 0.670 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.639352e-01 | 0.785 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 2.528464e-01 | 0.597 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.566390e-01 | 0.805 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 2.389673e-01 | 0.622 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.486386e-01 | 0.828 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.589538e-01 | 0.799 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 2.579065e-01 | 0.589 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 2.486191e-01 | 0.604 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.732254e-01 | 0.761 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.846597e-01 | 0.734 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 2.449873e-01 | 0.611 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 2.449873e-01 | 0.611 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 2.229664e-01 | 0.652 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.634061e-01 | 0.787 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.040808e-01 | 0.690 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.639352e-01 | 0.785 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 1.634061e-01 | 0.787 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 2.586461e-01 | 0.587 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 1.829019e-01 | 0.738 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 1.596062e-01 | 0.797 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 1.554001e-01 | 0.809 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.483715e-01 | 0.829 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 2.289397e-01 | 0.640 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.528464e-01 | 0.597 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.448604e-01 | 0.839 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.809917e-01 | 0.742 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 2.289397e-01 | 0.640 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 2.579065e-01 | 0.589 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.679118e-01 | 0.775 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 1.739342e-01 | 0.760 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 2.449873e-01 | 0.611 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.626293e-01 | 0.581 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 2.633486e-01 | 0.579 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.685779e-01 | 0.571 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 2.686075e-01 | 0.571 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 2.686075e-01 | 0.571 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 2.733908e-01 | 0.563 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 2.737130e-01 | 0.563 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.745602e-01 | 0.561 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.758930e-01 | 0.559 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.777614e-01 | 0.556 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.777614e-01 | 0.556 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.782330e-01 | 0.556 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 2.782330e-01 | 0.556 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.796266e-01 | 0.553 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.796266e-01 | 0.553 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.796266e-01 | 0.553 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 2.860723e-01 | 0.544 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.869935e-01 | 0.542 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.875373e-01 | 0.541 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 2.875373e-01 | 0.541 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.875373e-01 | 0.541 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 2.875373e-01 | 0.541 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 2.875373e-01 | 0.541 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 2.877200e-01 | 0.541 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.894384e-01 | 0.538 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.901637e-01 | 0.537 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.903292e-01 | 0.537 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.914333e-01 | 0.535 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 2.914333e-01 | 0.535 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.914333e-01 | 0.535 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 2.947593e-01 | 0.531 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.947593e-01 | 0.531 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 2.947593e-01 | 0.531 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.947593e-01 | 0.531 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 2.947593e-01 | 0.531 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 2.947593e-01 | 0.531 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 2.947593e-01 | 0.531 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.947593e-01 | 0.531 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.947593e-01 | 0.531 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 2.947593e-01 | 0.531 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.947593e-01 | 0.531 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 2.947593e-01 | 0.531 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 2.949984e-01 | 0.530 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 2.949984e-01 | 0.530 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 2.949984e-01 | 0.530 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 2.949984e-01 | 0.530 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.949984e-01 | 0.530 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 2.949984e-01 | 0.530 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 2.955970e-01 | 0.529 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.985068e-01 | 0.525 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.985068e-01 | 0.525 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.005721e-01 | 0.522 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.021548e-01 | 0.520 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.040959e-01 | 0.517 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 3.043199e-01 | 0.517 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 3.071586e-01 | 0.513 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.071586e-01 | 0.513 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.120299e-01 | 0.506 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 3.120299e-01 | 0.506 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 3.156905e-01 | 0.501 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.176086e-01 | 0.498 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.176086e-01 | 0.498 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 3.176086e-01 | 0.498 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.176086e-01 | 0.498 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 3.176086e-01 | 0.498 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 3.176086e-01 | 0.498 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 3.184640e-01 | 0.497 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 3.218284e-01 | 0.492 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.218284e-01 | 0.492 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 3.218284e-01 | 0.492 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.218284e-01 | 0.492 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 3.233344e-01 | 0.490 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 3.268646e-01 | 0.486 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.268646e-01 | 0.486 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.268646e-01 | 0.486 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.302940e-01 | 0.481 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.302940e-01 | 0.481 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.302940e-01 | 0.481 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 3.316303e-01 | 0.479 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 3.316303e-01 | 0.479 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 3.316303e-01 | 0.479 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 3.316303e-01 | 0.479 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.338053e-01 | 0.477 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.338053e-01 | 0.477 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.338053e-01 | 0.477 | 0 | 0 |
| Defective SLC26A2 causes chondrodysplasias | R-HSA-3560792 | 3.338053e-01 | 0.477 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.338053e-01 | 0.477 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 3.338053e-01 | 0.477 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 3.338053e-01 | 0.477 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 3.338053e-01 | 0.477 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.338053e-01 | 0.477 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 3.338053e-01 | 0.477 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.338053e-01 | 0.477 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.338053e-01 | 0.477 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.338053e-01 | 0.477 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 3.338053e-01 | 0.477 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.371862e-01 | 0.472 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.381681e-01 | 0.471 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.381681e-01 | 0.471 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 3.433212e-01 | 0.464 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 3.433212e-01 | 0.464 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 3.433212e-01 | 0.464 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.440370e-01 | 0.463 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 3.440370e-01 | 0.463 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 3.440370e-01 | 0.463 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 3.440370e-01 | 0.463 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 3.440370e-01 | 0.463 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 3.440370e-01 | 0.463 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.440370e-01 | 0.463 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 3.440370e-01 | 0.463 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.479092e-01 | 0.459 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.479092e-01 | 0.459 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.483651e-01 | 0.458 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.483651e-01 | 0.458 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.483651e-01 | 0.458 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 3.491110e-01 | 0.457 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 3.491110e-01 | 0.457 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.491904e-01 | 0.457 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.491904e-01 | 0.457 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 3.521792e-01 | 0.453 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 3.618519e-01 | 0.441 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 3.649774e-01 | 0.438 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 3.649774e-01 | 0.438 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.649774e-01 | 0.438 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.668463e-01 | 0.436 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 3.668463e-01 | 0.436 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.678876e-01 | 0.434 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 3.681932e-01 | 0.434 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 3.681932e-01 | 0.434 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 3.681932e-01 | 0.434 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 3.681932e-01 | 0.434 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 3.681932e-01 | 0.434 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.782431e-01 | 0.422 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 3.782431e-01 | 0.422 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 3.782431e-01 | 0.422 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 3.782431e-01 | 0.422 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.782431e-01 | 0.422 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.805548e-01 | 0.420 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 3.818704e-01 | 0.418 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 3.831591e-01 | 0.417 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.831591e-01 | 0.417 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.831591e-01 | 0.417 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.831591e-01 | 0.417 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 3.856211e-01 | 0.414 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.857032e-01 | 0.414 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.857032e-01 | 0.414 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.861546e-01 | 0.413 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 3.921478e-01 | 0.407 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 3.921478e-01 | 0.407 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 3.921478e-01 | 0.407 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 3.921478e-01 | 0.407 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 3.921478e-01 | 0.407 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 3.921478e-01 | 0.407 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 3.921478e-01 | 0.407 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.921478e-01 | 0.407 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 3.921478e-01 | 0.407 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 3.921478e-01 | 0.407 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 3.921478e-01 | 0.407 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.921478e-01 | 0.407 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 3.921478e-01 | 0.407 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 3.921478e-01 | 0.407 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 3.921478e-01 | 0.407 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 3.921478e-01 | 0.407 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 4.004306e-01 | 0.397 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.010185e-01 | 0.397 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 4.043837e-01 | 0.393 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 4.043837e-01 | 0.393 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 4.043837e-01 | 0.393 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.043837e-01 | 0.393 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 4.084303e-01 | 0.389 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 4.084969e-01 | 0.389 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 4.093863e-01 | 0.388 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 4.093863e-01 | 0.388 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.095747e-01 | 0.388 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 4.095747e-01 | 0.388 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 4.095747e-01 | 0.388 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 4.181725e-01 | 0.379 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 4.181725e-01 | 0.379 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 4.181725e-01 | 0.379 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 4.181725e-01 | 0.379 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 4.181725e-01 | 0.379 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 4.181725e-01 | 0.379 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 4.181725e-01 | 0.379 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 4.181725e-01 | 0.379 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 4.181725e-01 | 0.379 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.181725e-01 | 0.379 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 4.246078e-01 | 0.372 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.246078e-01 | 0.372 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.273947e-01 | 0.369 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.328235e-01 | 0.364 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 4.330631e-01 | 0.363 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.330631e-01 | 0.363 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.358251e-01 | 0.361 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 4.358251e-01 | 0.361 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.383085e-01 | 0.358 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.383085e-01 | 0.358 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 4.385973e-01 | 0.358 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 4.385973e-01 | 0.358 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 4.385973e-01 | 0.358 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 4.385973e-01 | 0.358 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 4.385973e-01 | 0.358 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 4.385973e-01 | 0.358 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 4.385973e-01 | 0.358 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 4.399425e-01 | 0.357 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 4.399425e-01 | 0.357 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 4.399425e-01 | 0.357 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.399425e-01 | 0.357 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.399425e-01 | 0.357 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 4.475159e-01 | 0.349 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 4.518477e-01 | 0.345 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 4.565720e-01 | 0.340 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.575367e-01 | 0.340 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.618063e-01 | 0.336 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 4.618063e-01 | 0.336 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 4.618063e-01 | 0.336 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.618063e-01 | 0.336 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.675228e-01 | 0.330 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 4.677330e-01 | 0.330 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 4.677330e-01 | 0.330 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 4.677330e-01 | 0.330 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 4.677330e-01 | 0.330 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 4.677330e-01 | 0.330 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 4.677330e-01 | 0.330 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 4.677330e-01 | 0.330 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 4.677330e-01 | 0.330 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 4.677330e-01 | 0.330 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 4.746524e-01 | 0.324 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 4.746524e-01 | 0.324 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 4.746524e-01 | 0.324 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 4.746524e-01 | 0.324 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 4.746524e-01 | 0.324 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 4.746524e-01 | 0.324 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 4.746524e-01 | 0.324 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 4.746524e-01 | 0.324 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.752515e-01 | 0.323 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 4.762399e-01 | 0.322 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 4.798395e-01 | 0.319 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 4.830348e-01 | 0.316 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 4.830348e-01 | 0.316 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 4.830348e-01 | 0.316 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 4.830348e-01 | 0.316 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 4.830348e-01 | 0.316 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.830348e-01 | 0.316 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.830348e-01 | 0.316 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 4.830348e-01 | 0.316 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 4.830348e-01 | 0.316 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.830348e-01 | 0.316 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 4.830348e-01 | 0.316 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.830348e-01 | 0.316 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 4.873691e-01 | 0.312 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.874233e-01 | 0.312 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.874233e-01 | 0.312 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 4.874233e-01 | 0.312 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 4.918597e-01 | 0.308 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 4.918597e-01 | 0.308 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.918597e-01 | 0.308 | 0 | 0 |
| 3-Methylcrotonyl-CoA carboxylase deficiency | R-HSA-9909438 | 4.918597e-01 | 0.308 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 4.918597e-01 | 0.308 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.918597e-01 | 0.308 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 4.918597e-01 | 0.308 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 4.918597e-01 | 0.308 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.918597e-01 | 0.308 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.918597e-01 | 0.308 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.918597e-01 | 0.308 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.918597e-01 | 0.308 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.918597e-01 | 0.308 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.918597e-01 | 0.308 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.918597e-01 | 0.308 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 4.918597e-01 | 0.308 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.926254e-01 | 0.307 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 4.928467e-01 | 0.307 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.945416e-01 | 0.306 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 4.945416e-01 | 0.306 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 4.965769e-01 | 0.304 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 4.965769e-01 | 0.304 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.066702e-01 | 0.295 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.083356e-01 | 0.294 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.083356e-01 | 0.294 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 5.083356e-01 | 0.294 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 5.083356e-01 | 0.294 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 5.083356e-01 | 0.294 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 5.083356e-01 | 0.294 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 5.083356e-01 | 0.294 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 5.094569e-01 | 0.293 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 5.125914e-01 | 0.290 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 5.125914e-01 | 0.290 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.154117e-01 | 0.288 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 5.218134e-01 | 0.282 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.247308e-01 | 0.280 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.247308e-01 | 0.280 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 5.247308e-01 | 0.280 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 5.247308e-01 | 0.280 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.247308e-01 | 0.280 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 5.247308e-01 | 0.280 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 5.247308e-01 | 0.280 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.251126e-01 | 0.280 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 5.252250e-01 | 0.280 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 5.252250e-01 | 0.280 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 5.252250e-01 | 0.280 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 5.264082e-01 | 0.279 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 5.372351e-01 | 0.270 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 5.372351e-01 | 0.270 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.372351e-01 | 0.270 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.408503e-01 | 0.267 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.408503e-01 | 0.267 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.521021e-01 | 0.258 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 5.521021e-01 | 0.258 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 5.538725e-01 | 0.257 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.562182e-01 | 0.255 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 5.562182e-01 | 0.255 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.562182e-01 | 0.255 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 5.562182e-01 | 0.255 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 5.562182e-01 | 0.255 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.562182e-01 | 0.255 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.562182e-01 | 0.255 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.562182e-01 | 0.255 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.562182e-01 | 0.255 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 5.562182e-01 | 0.255 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 5.562182e-01 | 0.255 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 5.562182e-01 | 0.255 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 5.562182e-01 | 0.255 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.562182e-01 | 0.255 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 5.564339e-01 | 0.255 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.585421e-01 | 0.253 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 5.612886e-01 | 0.251 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.643204e-01 | 0.248 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 5.650245e-01 | 0.248 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.650245e-01 | 0.248 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 5.650245e-01 | 0.248 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 5.650245e-01 | 0.248 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 5.650245e-01 | 0.248 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 5.650245e-01 | 0.248 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.650245e-01 | 0.248 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 5.650245e-01 | 0.248 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 5.650245e-01 | 0.248 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 5.678894e-01 | 0.246 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.720877e-01 | 0.243 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 5.720877e-01 | 0.243 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 5.720877e-01 | 0.243 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 5.720877e-01 | 0.243 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 5.763152e-01 | 0.239 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 5.786141e-01 | 0.238 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 5.786141e-01 | 0.238 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 5.786141e-01 | 0.238 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.903932e-01 | 0.229 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 5.903932e-01 | 0.229 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 5.957606e-01 | 0.225 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 5.990344e-01 | 0.223 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 6.017966e-01 | 0.221 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.019678e-01 | 0.220 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 6.019678e-01 | 0.220 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.019678e-01 | 0.220 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.019678e-01 | 0.220 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 6.019678e-01 | 0.220 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.019678e-01 | 0.220 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 6.023620e-01 | 0.220 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 6.023620e-01 | 0.220 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.023620e-01 | 0.220 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 6.023620e-01 | 0.220 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 6.023620e-01 | 0.220 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 6.023620e-01 | 0.220 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 6.023620e-01 | 0.220 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 6.023620e-01 | 0.220 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 6.023620e-01 | 0.220 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.042052e-01 | 0.219 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.042052e-01 | 0.219 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.042052e-01 | 0.219 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.042052e-01 | 0.219 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 6.042052e-01 | 0.219 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.074082e-01 | 0.217 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 6.110003e-01 | 0.214 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 6.110003e-01 | 0.214 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 6.110003e-01 | 0.214 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 6.110003e-01 | 0.214 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 6.110003e-01 | 0.214 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 6.124287e-01 | 0.213 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 6.124287e-01 | 0.213 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 6.124287e-01 | 0.213 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 6.124287e-01 | 0.213 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 6.124287e-01 | 0.213 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 6.124287e-01 | 0.213 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 6.124287e-01 | 0.213 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.124287e-01 | 0.213 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 6.124287e-01 | 0.213 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 6.124287e-01 | 0.213 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 6.124287e-01 | 0.213 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 6.124287e-01 | 0.213 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.147040e-01 | 0.211 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 6.185125e-01 | 0.209 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 6.185125e-01 | 0.209 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 6.222623e-01 | 0.206 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.230333e-01 | 0.205 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.288276e-01 | 0.201 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 6.293877e-01 | 0.201 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 6.304366e-01 | 0.200 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 6.304366e-01 | 0.200 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 6.304366e-01 | 0.200 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.304366e-01 | 0.200 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 6.372226e-01 | 0.196 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 6.372226e-01 | 0.196 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 6.372226e-01 | 0.196 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 6.504207e-01 | 0.187 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.506030e-01 | 0.187 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.506030e-01 | 0.187 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 6.524462e-01 | 0.185 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 6.524462e-01 | 0.185 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 6.524462e-01 | 0.185 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 6.524462e-01 | 0.185 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 6.525620e-01 | 0.185 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 6.574622e-01 | 0.182 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.615223e-01 | 0.179 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.615223e-01 | 0.179 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.615223e-01 | 0.179 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.615223e-01 | 0.179 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 6.615223e-01 | 0.179 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 6.615223e-01 | 0.179 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.615223e-01 | 0.179 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.615223e-01 | 0.179 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 6.615223e-01 | 0.179 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 6.615223e-01 | 0.179 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.615223e-01 | 0.179 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 6.615223e-01 | 0.179 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 6.615223e-01 | 0.179 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 6.615223e-01 | 0.179 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 6.615223e-01 | 0.179 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 6.615223e-01 | 0.179 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 6.615223e-01 | 0.179 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.615223e-01 | 0.179 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.690920e-01 | 0.175 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 6.696348e-01 | 0.174 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 6.696348e-01 | 0.174 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.710307e-01 | 0.173 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 6.750373e-01 | 0.171 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 6.750373e-01 | 0.171 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 6.750373e-01 | 0.171 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.750373e-01 | 0.171 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 6.774429e-01 | 0.169 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 6.830322e-01 | 0.166 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 6.830322e-01 | 0.166 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 6.830322e-01 | 0.166 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 6.851855e-01 | 0.164 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 6.872993e-01 | 0.163 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.906541e-01 | 0.161 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 6.965878e-01 | 0.157 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 6.965878e-01 | 0.157 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 6.993135e-01 | 0.155 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 6.996594e-01 | 0.155 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 6.996594e-01 | 0.155 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 6.996594e-01 | 0.155 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 6.996594e-01 | 0.155 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 6.996594e-01 | 0.155 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 7.027064e-01 | 0.153 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 7.043997e-01 | 0.152 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 7.043997e-01 | 0.152 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 7.043997e-01 | 0.152 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 7.043997e-01 | 0.152 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 7.043997e-01 | 0.152 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 7.043997e-01 | 0.152 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 7.043997e-01 | 0.152 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 7.043997e-01 | 0.152 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 7.043997e-01 | 0.152 | 0 | 0 |
| Metabolism of vitamin K | R-HSA-6806664 | 7.043997e-01 | 0.152 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 7.043997e-01 | 0.152 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 7.043997e-01 | 0.152 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 7.043997e-01 | 0.152 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.047476e-01 | 0.152 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.047476e-01 | 0.152 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 7.047476e-01 | 0.152 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.071503e-01 | 0.150 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.071503e-01 | 0.150 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 7.170937e-01 | 0.144 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 7.215238e-01 | 0.142 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 7.273812e-01 | 0.138 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 7.273812e-01 | 0.138 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 7.273812e-01 | 0.138 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.273812e-01 | 0.138 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.273812e-01 | 0.138 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 7.273812e-01 | 0.138 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 7.274532e-01 | 0.138 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 7.274532e-01 | 0.138 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 7.294545e-01 | 0.137 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.298341e-01 | 0.137 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.298341e-01 | 0.137 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.298341e-01 | 0.137 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.353168e-01 | 0.134 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 7.363206e-01 | 0.133 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 7.383625e-01 | 0.132 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 7.418477e-01 | 0.130 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.418477e-01 | 0.130 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.418477e-01 | 0.130 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 7.418477e-01 | 0.130 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 7.418477e-01 | 0.130 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.418477e-01 | 0.130 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 7.418477e-01 | 0.130 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.418477e-01 | 0.130 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 7.418477e-01 | 0.130 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 7.418477e-01 | 0.130 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.418477e-01 | 0.130 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 7.418477e-01 | 0.130 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 7.446251e-01 | 0.128 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 7.511123e-01 | 0.124 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.529015e-01 | 0.123 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.529015e-01 | 0.123 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 7.529015e-01 | 0.123 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 7.529015e-01 | 0.123 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 7.529015e-01 | 0.123 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 7.529015e-01 | 0.123 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 7.529015e-01 | 0.123 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.549947e-01 | 0.122 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.549947e-01 | 0.122 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 7.567416e-01 | 0.121 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 7.608304e-01 | 0.119 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 7.614411e-01 | 0.118 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 7.614411e-01 | 0.118 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.645783e-01 | 0.117 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.667463e-01 | 0.115 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 7.678028e-01 | 0.115 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 7.678028e-01 | 0.115 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 7.710226e-01 | 0.113 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.710226e-01 | 0.113 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.745535e-01 | 0.111 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.745535e-01 | 0.111 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.745535e-01 | 0.111 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 7.745535e-01 | 0.111 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.745535e-01 | 0.111 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 7.745535e-01 | 0.111 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 7.745535e-01 | 0.111 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 7.745535e-01 | 0.111 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.745535e-01 | 0.111 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 7.745535e-01 | 0.111 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 7.745535e-01 | 0.111 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 7.745535e-01 | 0.111 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.745535e-01 | 0.111 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 7.745535e-01 | 0.111 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.750876e-01 | 0.111 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.763333e-01 | 0.110 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 7.763333e-01 | 0.110 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 7.763333e-01 | 0.110 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.763333e-01 | 0.110 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 7.763333e-01 | 0.110 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.851591e-01 | 0.105 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 7.888511e-01 | 0.103 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.888511e-01 | 0.103 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 7.890272e-01 | 0.103 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 7.892170e-01 | 0.103 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.896100e-01 | 0.103 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.896100e-01 | 0.103 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.902063e-01 | 0.102 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.902063e-01 | 0.102 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.902063e-01 | 0.102 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.913064e-01 | 0.102 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 7.953205e-01 | 0.099 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 7.977960e-01 | 0.098 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 7.977960e-01 | 0.098 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 7.977960e-01 | 0.098 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 7.977960e-01 | 0.098 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 7.977960e-01 | 0.098 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.001225e-01 | 0.097 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 8.031174e-01 | 0.095 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 8.031174e-01 | 0.095 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 8.031174e-01 | 0.095 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 8.031174e-01 | 0.095 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 8.031174e-01 | 0.095 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 8.031174e-01 | 0.095 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 8.031174e-01 | 0.095 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 8.031174e-01 | 0.095 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 8.031174e-01 | 0.095 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 8.031174e-01 | 0.095 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.043201e-01 | 0.095 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.052985e-01 | 0.094 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 8.069249e-01 | 0.093 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.069249e-01 | 0.093 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.069249e-01 | 0.093 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 8.174124e-01 | 0.088 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 8.174124e-01 | 0.088 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 8.174124e-01 | 0.088 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 8.174124e-01 | 0.088 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 8.174124e-01 | 0.088 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 8.174124e-01 | 0.088 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 8.174124e-01 | 0.088 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.191920e-01 | 0.087 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.230219e-01 | 0.085 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 8.230219e-01 | 0.085 | 1 | 1 |
| Aquaporin-mediated transport | R-HSA-445717 | 8.231304e-01 | 0.085 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 8.280637e-01 | 0.082 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.280637e-01 | 0.082 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.280637e-01 | 0.082 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.280637e-01 | 0.082 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 8.280637e-01 | 0.082 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.280637e-01 | 0.082 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.287222e-01 | 0.082 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.317915e-01 | 0.080 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 8.324884e-01 | 0.080 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.324884e-01 | 0.080 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 8.353056e-01 | 0.078 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.353056e-01 | 0.078 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 8.353056e-01 | 0.078 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 8.353056e-01 | 0.078 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.379581e-01 | 0.077 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.379581e-01 | 0.077 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.379581e-01 | 0.077 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 8.379581e-01 | 0.077 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.385532e-01 | 0.076 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.385532e-01 | 0.076 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.447031e-01 | 0.073 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 8.498504e-01 | 0.071 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 8.498504e-01 | 0.071 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 8.498504e-01 | 0.071 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.498504e-01 | 0.071 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 8.498504e-01 | 0.071 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.498504e-01 | 0.071 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.498504e-01 | 0.071 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.498504e-01 | 0.071 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 8.515973e-01 | 0.070 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 8.515973e-01 | 0.070 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 8.515973e-01 | 0.070 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 8.515973e-01 | 0.070 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 8.517924e-01 | 0.070 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.539347e-01 | 0.069 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 8.539347e-01 | 0.069 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.552302e-01 | 0.068 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 8.552302e-01 | 0.068 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 8.643776e-01 | 0.063 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.645846e-01 | 0.063 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 8.664060e-01 | 0.062 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 8.664060e-01 | 0.062 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.664060e-01 | 0.062 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.683315e-01 | 0.061 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 8.688776e-01 | 0.061 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.688776e-01 | 0.061 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.700474e-01 | 0.060 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 8.720960e-01 | 0.059 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.763941e-01 | 0.057 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.798459e-01 | 0.056 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 8.798459e-01 | 0.056 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 8.798459e-01 | 0.056 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 8.810824e-01 | 0.055 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 8.842205e-01 | 0.053 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 8.854945e-01 | 0.053 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 8.854945e-01 | 0.053 | 0 | 0 |
| Beta oxidation of myristoyl-CoA to lauroyl-CoA | R-HSA-77285 | 8.854945e-01 | 0.053 | 0 | 0 |
| Beta oxidation of palmitoyl-CoA to myristoyl-CoA | R-HSA-77305 | 8.854945e-01 | 0.053 | 0 | 0 |
| Acetylation | R-HSA-156582 | 8.854945e-01 | 0.053 | 0 | 0 |
| Proline catabolism | R-HSA-70688 | 8.854945e-01 | 0.053 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.854945e-01 | 0.053 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.854945e-01 | 0.053 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.854945e-01 | 0.053 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.854945e-01 | 0.053 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.856179e-01 | 0.053 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.872835e-01 | 0.052 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 8.886870e-01 | 0.051 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.920260e-01 | 0.050 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 8.920260e-01 | 0.050 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 8.920260e-01 | 0.050 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.950610e-01 | 0.048 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.967360e-01 | 0.047 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 8.973003e-01 | 0.047 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 9.000065e-01 | 0.046 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 9.000065e-01 | 0.046 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 9.000065e-01 | 0.046 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 9.000065e-01 | 0.046 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 9.000065e-01 | 0.046 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 9.000065e-01 | 0.046 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 9.000065e-01 | 0.046 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 9.000065e-01 | 0.046 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 9.000065e-01 | 0.046 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 9.000065e-01 | 0.046 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 9.000065e-01 | 0.046 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 9.000065e-01 | 0.046 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.000612e-01 | 0.046 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.007573e-01 | 0.045 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.030497e-01 | 0.044 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.030497e-01 | 0.044 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.030497e-01 | 0.044 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.030497e-01 | 0.044 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.057124e-01 | 0.043 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.057124e-01 | 0.043 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.065112e-01 | 0.043 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.065112e-01 | 0.043 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.108059e-01 | 0.041 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 9.108059e-01 | 0.041 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 9.126800e-01 | 0.040 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 9.126800e-01 | 0.040 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.126800e-01 | 0.040 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 9.126800e-01 | 0.040 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 9.126800e-01 | 0.040 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 9.126800e-01 | 0.040 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 9.126800e-01 | 0.040 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 9.126800e-01 | 0.040 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.126800e-01 | 0.040 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 9.126800e-01 | 0.040 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.127148e-01 | 0.040 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.130143e-01 | 0.040 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.130143e-01 | 0.040 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.149671e-01 | 0.039 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.194648e-01 | 0.036 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.220113e-01 | 0.035 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 9.220113e-01 | 0.035 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.220113e-01 | 0.035 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.220113e-01 | 0.035 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.220113e-01 | 0.035 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.227205e-01 | 0.035 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 9.237479e-01 | 0.034 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 9.237479e-01 | 0.034 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 9.237479e-01 | 0.034 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 9.237479e-01 | 0.034 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.237479e-01 | 0.034 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.237479e-01 | 0.034 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.250091e-01 | 0.034 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.298213e-01 | 0.032 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.298213e-01 | 0.032 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.301258e-01 | 0.031 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.301258e-01 | 0.031 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.320159e-01 | 0.031 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.324833e-01 | 0.030 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.333644e-01 | 0.030 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.333644e-01 | 0.030 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.334135e-01 | 0.030 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 9.334135e-01 | 0.030 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.334135e-01 | 0.030 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.334135e-01 | 0.030 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.334135e-01 | 0.030 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.334135e-01 | 0.030 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.363173e-01 | 0.029 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.374368e-01 | 0.028 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.389195e-01 | 0.027 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.390179e-01 | 0.027 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.415768e-01 | 0.026 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.418543e-01 | 0.026 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.418543e-01 | 0.026 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 9.418543e-01 | 0.026 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 9.418543e-01 | 0.026 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.418543e-01 | 0.026 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.418543e-01 | 0.026 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | R-HSA-77288 | 9.418543e-01 | 0.026 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 9.418543e-01 | 0.026 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.418543e-01 | 0.026 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 9.418543e-01 | 0.026 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.418543e-01 | 0.026 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.422536e-01 | 0.026 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.422536e-01 | 0.026 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.431565e-01 | 0.025 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.440177e-01 | 0.025 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.440177e-01 | 0.025 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.472095e-01 | 0.024 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.477064e-01 | 0.023 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.477064e-01 | 0.023 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 9.492256e-01 | 0.023 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.492256e-01 | 0.023 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.492256e-01 | 0.023 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 9.492256e-01 | 0.023 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.492256e-01 | 0.023 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.492256e-01 | 0.023 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.492256e-01 | 0.023 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.517180e-01 | 0.021 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.519236e-01 | 0.021 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.526155e-01 | 0.021 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.526155e-01 | 0.021 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.526155e-01 | 0.021 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.534546e-01 | 0.021 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.552540e-01 | 0.020 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.556628e-01 | 0.020 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.556628e-01 | 0.020 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.559489e-01 | 0.020 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.598624e-01 | 0.018 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.603849e-01 | 0.018 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.611409e-01 | 0.017 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.612188e-01 | 0.017 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.612188e-01 | 0.017 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.612188e-01 | 0.017 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.612188e-01 | 0.017 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.612842e-01 | 0.017 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.612842e-01 | 0.017 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 9.612842e-01 | 0.017 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.612842e-01 | 0.017 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.612842e-01 | 0.017 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.612842e-01 | 0.017 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.612842e-01 | 0.017 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.620456e-01 | 0.017 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.643122e-01 | 0.016 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.661932e-01 | 0.015 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.661932e-01 | 0.015 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.661932e-01 | 0.015 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.661932e-01 | 0.015 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.681524e-01 | 0.014 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.683369e-01 | 0.014 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.704800e-01 | 0.013 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.704800e-01 | 0.013 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.715929e-01 | 0.013 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.737658e-01 | 0.012 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.742072e-01 | 0.011 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.742234e-01 | 0.011 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.742234e-01 | 0.011 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.746732e-01 | 0.011 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.746732e-01 | 0.011 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.748766e-01 | 0.011 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.762049e-01 | 0.010 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.762312e-01 | 0.010 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.774293e-01 | 0.010 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.774923e-01 | 0.010 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.774923e-01 | 0.010 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.774923e-01 | 0.010 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.774923e-01 | 0.010 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.779674e-01 | 0.010 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.780610e-01 | 0.010 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.798736e-01 | 0.009 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.799845e-01 | 0.009 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.799845e-01 | 0.009 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.802096e-01 | 0.009 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.803468e-01 | 0.009 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.803468e-01 | 0.009 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.803468e-01 | 0.009 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.803468e-01 | 0.009 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.816689e-01 | 0.008 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.818264e-01 | 0.008 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.818264e-01 | 0.008 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.820966e-01 | 0.008 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.820966e-01 | 0.008 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.828395e-01 | 0.008 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.828395e-01 | 0.008 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.828395e-01 | 0.008 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.828395e-01 | 0.008 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 9.850161e-01 | 0.007 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.850161e-01 | 0.007 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.850161e-01 | 0.007 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.858208e-01 | 0.006 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.862377e-01 | 0.006 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.869167e-01 | 0.006 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.869167e-01 | 0.006 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 9.869167e-01 | 0.006 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.869167e-01 | 0.006 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.869167e-01 | 0.006 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.869167e-01 | 0.006 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.870457e-01 | 0.006 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.873883e-01 | 0.006 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.884270e-01 | 0.005 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.885764e-01 | 0.005 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.885764e-01 | 0.005 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.885764e-01 | 0.005 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.885764e-01 | 0.005 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.887864e-01 | 0.005 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.887864e-01 | 0.005 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.894514e-01 | 0.005 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.896393e-01 | 0.005 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 9.900256e-01 | 0.004 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.900256e-01 | 0.004 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.912581e-01 | 0.004 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.912911e-01 | 0.004 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.912911e-01 | 0.004 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.915567e-01 | 0.004 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.917835e-01 | 0.004 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.918133e-01 | 0.004 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.930140e-01 | 0.003 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.933608e-01 | 0.003 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.933608e-01 | 0.003 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.937982e-01 | 0.003 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.938185e-01 | 0.003 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.942033e-01 | 0.003 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.947825e-01 | 0.002 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.953247e-01 | 0.002 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.955259e-01 | 0.002 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.955812e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.956681e-01 | 0.002 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.961060e-01 | 0.002 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.961420e-01 | 0.002 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.961420e-01 | 0.002 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.961585e-01 | 0.002 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.961585e-01 | 0.002 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.963056e-01 | 0.002 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.963056e-01 | 0.002 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.966316e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.970362e-01 | 0.001 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.970592e-01 | 0.001 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.970592e-01 | 0.001 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.970592e-01 | 0.001 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.971083e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.972625e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.973042e-01 | 0.001 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.973122e-01 | 0.001 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.974325e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.974325e-01 | 0.001 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.974325e-01 | 0.001 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.977584e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.980430e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.982834e-01 | 0.001 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.982914e-01 | 0.001 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.983209e-01 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.983381e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.984665e-01 | 0.001 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.984665e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.984665e-01 | 0.001 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.985263e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.985431e-01 | 0.001 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.985742e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.986305e-01 | 0.001 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.986305e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.986977e-01 | 0.001 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.986977e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.988631e-01 | 0.000 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.990075e-01 | 0.000 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.990075e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.991072e-01 | 0.000 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.991335e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.991608e-01 | 0.000 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.992436e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.992553e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.993088e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.993828e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.993828e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.994235e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.994604e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.995106e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.995178e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.996165e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.996207e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.996237e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.996652e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.996652e-01 | 0.000 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.996652e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.997407e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.997407e-01 | 0.000 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.997773e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.998216e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.998303e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.998312e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.998871e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.998871e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.998944e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.999015e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999020e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.999140e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.999152e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999258e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999568e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999605e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999620e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999620e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999668e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999682e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999845e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999853e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999872e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999902e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999902e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999921e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999924e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999927e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999941e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999948e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999953e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999969e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999973e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999983e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999987e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999990e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999993e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999994e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999995e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999996e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999997e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999998e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999998e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |